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INTRODUCTION
1. INTRODUCTION
The buccal route has been used for many years to deliver drugs such as certain steroids
that  are  subjected  to  first-pass  metabolism.  The buccal  route  has  the  advantage  of  allowing
excellent  accessibility,  reasonable  patient  acceptance  and  compliance,  avoids  first-pass
metabolism and involves a relatively robust mucosa1. 
 Buccal delivery is defined as drug administration through the mucosal membranes lining
the cheeks (buccal mucosa).
Based  on  our  current  understanding  of  biochemical  and  physiological  aspects  of
absorption  and  metabolism  of  many  biotechnologically  -  produced  drugs,  they  cannot  be
delivered effectively through the conventional oral route. After oral administration many drugs
are  subjected  to  presystemic  clearance  extensive  in  liver,  which  often  leads  to  a  lack  of
significant correlation between membrane permeability, absorption, and bioavailability.
Difficulties associated with parenteral  delivery and poor oral  availability provided the
impetus for exploring alternative routes for the delivery of such drugs. These include routes such
as pulmonary, ocular, nasal, rectal, buccal, sublingual, vaginal, and transdermal. In absence of
external stimuli to facilitate absorption, use of these alternative routes had limited success.
1.1. The oral cavity
Dept. of Pharmaceutics,K.M. College of Pharmacy,Madurai 
 1
INTRODUCTION
The functions of the oral cavity (also referred to as the "buccal cavity")2 includes the analysis
of potential foodstuffs, mechanical processing, lubrication and digestion. The oral cavity consists
of two regions, the outer oral vestibule which is bounded by the cheeks, lips, teeth and gingiva
(gums) and the oral cavity proper which extends from the teeth and gums back to the fauces
(which lead on to the pharynx) with the roof comprising the hard and soft palates. The tongue
projects from the floor of the cavity. The buccal mucosa refers to the membrane lining the inside
of the cheek, and the term "buccal drug delivery" refers to drug release which can occur when a
dosage form is placed in the outer vestibule between the buccal mucosa and gingival. 
The outer surface of the oral cavity is a mucous membrane consisting of an epithelium,
basement membrane and lamina propria overlying a submucosa containing blood vessels and
nerves.  The  mucosa  can  be  divided  into  three  types:  the masticatory  mucosa,  found  on  the
gingiva  and  hard  palate;  the  lining  mucosa  found  on  the  lips,  cheek,  floor  of  the  mouth,
undersurface of the tongue and the soft palate; and the specialised mucosa found on the upper
surface of the tongue and parts of the lips. All consist of a squamous stratified epithelium, many
cell layers thick (40-50 for the buccal mucosa) overlying a connective tissue layer, the lamina
propria. In the case of the masticatory mucosa the outer layers are keratinised and may be said to
be similar (but not identical) to skin. The total surface area of the oral mucosa is about 100 cm
and the buccal mucosa makes up of about a third of this.  
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INTRODUCTION
   
FIG 1. Cross sectional area of the buccal mucosa
The biochemistry of the oral mucosa, all the layers of the oral mucosa contain a large
amount  of  protein  in  the  form of  tonafilaments,  consisting  of  at  least  seven  proteins  called
"keratins"  with molecular  sizes of  40 70 KDa.  The difference  between keratinised and non-
keratinised epithelia is merely the difference in the molecular size of these keratins. Cells of
nonkeratinised  epithelia  contain  lower-molecular-weight  proteins  while  those  in  keratinised
epithelia contain mainly higher-molecular-weight keratins. The lipid content of the cells varies
between tissues. The non-keratinised buccal and sublingual mucosa contain polar lipids while the
keratinised  gingival  and  palatal  mucosa  contain  non-polar  lipids.  The  intercellular  material
between the superficial epithelial layers is extruded by a unique organelle called a "membrane-
coating granule". It has been shown in rat keratinised epithelium that the lamella contents of the
membrane-coating granules mix with existing material and form broad sheets in the intercellular
spaces.  These sheets are orientated parallel  to the cell membrane and therefore may act as a
Dept. of Pharmaceutics,K.M. College of Pharmacy,Madurai 
 3
INTRODUCTION
barrier to permeability. The surface of the oral cavity is constantly bathed with a stream of saliva
(approximately  1  liter  per  day)  produced  by the  salivary  glands.  The major  salivary glands,
producing up to 90% of the saliva, are the pairs of parotid, sub maxillary (sub mandibular) and
sublingual glands. The parotid glands are situated some way from, but drain into, the oral cavity
via long ducts that open onto the inner surface of the cheek. The sub maxillary glands lie below
the lower  jaw and release saliva through ducts on each side of the floor of  the mouth.  The
sublingual glands are located below the tongue with several ducts emptying onto the floor of the
mouth. 
The importance of saliva is illustrated in a condition called "xerostomia" (dry mouth)
where  patients  complain  of  a  variety  of  symptoms  including  sore  mouth,  oral  infections,
difficulty in talking, adhesion of the tongue to the side or roof of the mouth, and dental caries.
Chemically, saliva consists of 99.5% water with 0.5% solutes. The solutes include ions
(sodium, potassium, calcium, magnesium, phosphate, bicarbonate and chloride), dissolved gases,
urea, uric acid, serum albumin, globulin, mucin, and enzymes (lysozyme and amylase (ptyalin).
The  nature  of  the  secretions  varies  from  gland  to  gland;  the  parotid  glands  produce
predominantly an amylase-containing watery secretion while the buccal and sublingual glands
produce mainly a viscous saliva containing mucin with little enzymic activity. The submaxillary
glands  have  an  intermediate  secretion  containing  both  amylase  and  mucin.  When  food  is
ingested,  secretion  increases  so  that  the  saliva  can  lubricate,  dissolve  and  bring  about  the
chemical breakdown of food. 
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Saliva can be produced at a rate of up to 7 ml min- 1, 50% coming from the parotid
gland.  Thus  the  nature  of  the  salivary  secretion  may alter  from viscous  to  watery  (and  the
enzyme content is also variable). The salivary pH will also vary from 6.2 to 7.4 (from low to
high flow rates) although bacteria around the teeth may produce a lower localised pH.
The glycoproteins in saliva can be divided into two groups: those of mucous cell origin
which have a high molecular weight and are heavily glycosylated and those of serous cell origin
which have a lower molecular  weight  and contain less than 50% carbohydrate.  The salivary
mucin glycoprotein MG1 consists of several disulphide-linked subunits containing a protein core
with 4-16 oligosaccharide side-chain units. Its molecular size is over 1000 kDa, and it contains
approximately 15% protein, 78% carbohydrate with about 5-10% covalently bound fatty acids. A
smaller mucin glycoprotein (MG2) has been identified from submaxillary and sublingual saliva.
This contains 30% protein and 68% carbohydrate and has a molecular weight of 200-250 kDa. It
consists of a single peptide chain with 2-7 oligosaccharide side-chain units. Another important
glycoprotein  found in human parotid saliva is proline-rich glycoprotein (PRG). This contains
60% protein and 30% carbohydrate and is 38.9 kDa in size.
Components of saliva are adsorbed onto the surface of the oral mucosa to form a salivary
pellicle 0.1-0.7 mm thick.  This pellicle coats all surfaces in the mouth and is a multilayered
structure. Initially, salivary macromolecules are selectively adsorbed onto the mucosal surface,
then these molecules complex with other molecules in the ambient saliva. It has been proposed
that these salivary components may be covalently cross linked to the epithelial cell surface and to
each  other  by  the  actions  of  transglutaminases.  MG1  functions  at  the  hard  and  soft  tissue
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interfaces  to  provide  a  permeability  barrier  for  protection  against  environmental  insult  and
desiccation. The nature of the salivary pellicle (i.e. its effectiveness in increasing the wet ability
of a surface) has been seen to change throughout the day. The oral cavity contains large numbers
of microorganisms and the salivary pellicle has been shown to be a determinant in bacterial
adhesion. 
Buccal Mucosa: Environment3 
The oral cavity is marked by the presence of saliva produced by the salivary glands and
mucus which is secreted by the major and minor salivary glands as part of saliva. 
Role of Saliva 
 Protective fluid for all tissues of the oral cavity. 
 Continuous mineralization / demineralization of the tooth enamel . 
 To hydrate oral mucosal dosage forms. 
Role of Mucus 
 Made up of proteins and carbohydrates. 
 Cell-cell adhesion 
 Lubrication 
 Bioadhesion of mucoadhesive drug delivery systems 
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Permeability of Drugs Through Buccal Mucosa4 
There are two possible routes of drug absorption through the squalors stratified epithelium of
the oral mucosa: 
i. Transcellular (intracellular, passing through the cell) and 
ii. Paracellular (intercellular, passing around the cell). 
Permeation across the buccal mucosa has been reported to be mainly by the paracellular route
through the intercellular lipids produced by membrane-coating granules. 
Although passive diffusion is the main mechanism of drug absorption, specialized transport
mechanisms have been reported to exist in other oral mucosa (that of the tongue) for a few drugs
and nutrients; glucose and cefadroxil were shown to be absorbed in this way. 
The  buccal  mucosa  is  a  potential  site  for  the  controlled  delivery  of  hydrophilic
macromolecular therapeutic agents (biopharmaceuticals) such as peptides, oligonucleotides and
polysaccharides.  However,  these high  molecular  weight  drugs  usually have low permeability
leading to a low bioavailability, and absorption enhancers may be required to overcome this. 
The  buccal  mucosa  also  contains  proteases  that  may  degrade  peptide-based  drugs.  In
addition, the salivary enzymes may also reduce stability. 
Disease  states  where  the  mucosa  is  damaged  would  also  be  expected  to  increase
permeability. This would be particularly true in conditions that result in erosion of the mucosa
such as lichen planus, pemphigus, viral infections and allergic reactions. 
Dept. of Pharmaceutics,K.M. College of Pharmacy,Madurai 
 7
INTRODUCTION
1.3. Drug delivery via the oral cavity5
The oral cavity can be used for local therapy (treatment of oral infections, dental caries,
mouth ulcers, and stomatitis) and systemic therapy. The buccal route is of particular interest with
regard to the systemic delivery of small molecules that are subjected to first-pass metabolism, or
for the administration of proteins and peptides. The multilayered structure and mainly protective
role of the mucosa within the oral cavity would imply that it would not be as good a site for drug
absorption as other single cell layer mucosa, e.g. those found in the small and large intestines. 
In keratinized oral mucosal tissue as with skin, the keratinized upper layer is the major
barrier  to  drug  absorption.  The  lamina  propria  is  believed  to  offer  little  resistance  to  drug
permeation.  Regional  variations  in  oral  mucosal  drug  absorption  are  consistent  with  the
differences in the thickness and composition of the mucosa within the oral cavity. 
Fig 2. Schematic representation of penetration routes in buccal drug delivery.
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The salivary pellicle may also act as a barrier for drug absorption. It is known that the
salivary pellicle protects the mucosa from acids and enzymes, and there is evidence from animal
studies that the absence of this layer  allows the diffusion of various compounds through the
mucosa, including acridine orange and benzpyrine. 
The  steady-state  permeability  coefficient  for  three  peptides—thyrotrophin  releasing
hormone, DDAVP (1-deamino-8-D-arginine vasopressin) and insulin--have been calculated for
the buccal route. The buccal mucosa was less permeable than nasal or intestinal mucosa, and
only DDAVP gave calculated steady-state levels in excess of the therapeutic levels, due mainly
to its comparatively long half-life. The use of penetration enhancers has been investigated as a
suitable method for improving the penetration of non-peptide drugs through the buccal mucosa. 
 Laureth-9,  sodium lauryl  sulphate and steroidal  detergents  (e.g.  sodium glycocholate)
were found to be the most effective enhancers at pH 7.4 and their most effective formulations
gave insulin levels one-quarter to one-third as effective as an intramuscular injection. 
1.4. Advantages Buccal-adhesive dosage forms.
 Significant reduction in dose related side effects.
 It provides direct entry of drug into systemic circulation.
 Drug  degradation  in  harsh  gastrointestinal  environment  can  be  circumvented  by
administering the drug via buccal route.
 Drug absorption can be terminated in case of emergency.
 It offers passive system, which does not require activation. 
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 Rapid cellular recovery following local stress or damage. 
 Ability to withstand environmental extremes like change in pH, temperature etc. 
 Sustained drug delivery. 
 The potential for delivery of peptide molecules unsuitable for the oral route. 
1.5. Limitations 
 Once placed at the absorption site, the dosage form should not be disturbed. 
 Drugs which are unstable at buccal pH and which irritate the mucosa or have a bitter or
unpleasant taste or an obnoxious odor cannot be administered by this route. 
 Over  hydration  may lead  to  formation  of  slippery  surface  and  structural  integrity  of
formulation may get disrupted. 
1.6. Mucosal-adhesive materials 6
Mucosal-adhesive  materials  are  generally  hydrophilic  macromolecules  that  contain
numerous hydrogen-bond-forming groups. The presence of carboxyl groups and a molecular size
greater than 100 kDa favor adhesion. In most cases these materials require moisture to become
adhesive  but  may  excessively  hydrate  to  form  slippery  mucilage,  and  lose  their  adhesive
properties. Several strategies (i.e. the inclusion of a hydrophobic component or a cross-linking
agent) have been used to prevent excess hydration.
Some of the most extensively studied mucosal adhesives are the poly(acrylic acids), e.g.
Carbopol 934 and polycarbophil. The high concentration of carboxyl groups in a dry tablet of
poly(acrylic acid) would be predicted to generate a low surface pH on moistening, and pH values
of between 2 and 3 have been detected in our laboratories.  A low pH would be expected to
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damage a contacting mucosal surface, and this has been reported in an in vivo study. Salts and
bases have been included in poly(acrylic acid)-containing formulations to raise the pH, but the
presence  of  predominantly  ionised  carboxyl  groups  would  result  in  a  loss  of  the  adhesive
properties. Thus the ultimate suitability of poly(acrylic acid) for use as a bioadhesive component
in a pharmaceutical formulation may be questioned. 
Other  anionic  mucosal-adhesive  materials  include  sodium  carboxymethylcellulose,
sodium alginate, and maleic anhydride copolymers. Non-ionic polymers on the whole tend to be
weaker  adhesives,  and  these  include  hydroxypropylmethylcellulose,  hydroxypropylcellulose,
methylcellulose,  poly(ethylene  oxide),  poly(vinyl  alcohol),  and  starch.  Chitosan  and
diethylaminoethyl-dextran  are  examples  of  cationic  materials  that  have  been  proposed  as
mucosal-adhesive polymers.
1.6.2. Mechanism of mucosal adhesion7
Mucosal-adhesive materials are called "wet" adhesives in that they will adhere to most
surfaces  on  moistening.  The  various  theories  of  bioadhesion  are  the  electronic  theory,  the
adsorption theory, the wetting theory, the diffusion theory and the fracture theory. It has been
envisaged that for dosage forms to adhere to mucous membranes, they must first interact with the
overlying layer of mucus.
Mucoadhesion is proposed to occur in three stages. Initially,  an intimate contact  must
form  between  the  mucoadhesive  and  mucus  (i.e.  they  must  "wet"  each  other),  then  the
mucus/mucoadhesive  macromolecules  interpenetrate,  and  finally  the  molecules  interact  with
each other by secondary non-covalent bonds. It would be predicted that the mucus layer would
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be the weakest component of the mucoadhesive joint. If interpenetration is an important stage in
mucoadhesive bond formation, then including bioadhesive polymers into a mucus gel would be
expected to increase its resistance to deformation, thus strengthening the adhesive joint. 
With regard to the buccal cavity, dosage forms can be placed directly in position, and so
force can be applied to ensure that the two surfaces come into intimate contact. Pressure will also
be applied by the cheek and gums and it has been proposed that very little adhesive force is
required to hold a dosage form in place.
Its main role in the adhesive process may therefore be to provide the moisture necessary
for adhesion. Thus the surface of the oral cavity may be considered as a moist membrane to
which these "wet" adhesives will attach, by predominantly Secondary interactions. Hydration is
required to allow the molecules to attain a degree of flexibility to allow good contact with, and
then interaction with, the epithelial cell surface. It is worth noting that wet cellophane, Visking
tubing and other moist surfaces have been successfully used as a model for the oral mucosa in
adhesion studies.
The  existing  interpenetration  theory  of  mucoadhesion  may  not  be  appropriate  for
explaining  the  adhesion  of  dry  dosage  forms  within  the  oral  cavity.  It  may  also  be  more
appropriate  to restrict the term "mucoadhesion" to describing the adhesion of hydrated dosage
forms to those mucous membranes having a substantial mucus layer. The terms "bioadhesion" or
"mucosal adhesion" may be more suitable to describe adhesion to the mucosa of the oral cavity.
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1.7. Buccal-adhesive dosage forms8
The following requirements for buccal-adhesive dosage forms: (a) they should be flexible
enough to follow the movement of the cheek; (b) they should be adhesive enough to be retained
on the buccal mucosa but not so strong that the mucosa is damaged on removal; (c) they should
be biocompatible and not cause irritation.
Buccal-adhesive  dosage  forms  can  deliver  the  drug  either  locally  to  treat  conditions
within the buccal cavity or systemically via the mucosa. It  is often a requirement that buccal-
adhesive  dosage  forms  should  remain  adhesive  and  allow a  controlled  delivery  of  drug  for
prolonged periods. For systemic therapy, dosage forms can be designed to deliver drugs only to
the associated section of  adhering mucosa (in the buccal  pouch this  may be the buccal  and
gingival mucosa), or to release the drug into the saliva prior to absorption. When in place, the
dosage form will need to withstand mechanical abrasion by the surrounding tissue, the effect of
continued contact with saliva (although this should be less of a problem in the upper regions of
the buccal pouch) and the presence of food and drink at mealtimes.
Therefore,  for  sustained  drug  delivery,  buccal-adhesive  formulations  must  contain
elements that remain adhesive for a prolonged period, regulate the rate and direction of drug
delivery. Another major problem with formulating dry dosage forms containing "wet" adhesives
is that swelling occurs on hydration,  and this may disrupt the integrity of these multilayered
formulations. 
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Structure And Design Of Buccal Dosage Form 9  
Buccal Dosage form can be of 
1. Matrix type: The buccal patch designed in a matrix configuration contains drug, adhesive,
and additives mixed together 
2.  Reserviour type: The buccal patch designed in a reservoir system contains a cavity for the
drug and additives separate from the adhesive. An impermeable backing is applied to control the
direction of drug delivery; to reduce patch deformation and disintegration while in the mouth;
and to prevent drug loss. 
Additionally, the patch can be constructed to undergo minimal degradation in the mouth,
or can be designed to dissolve almost immediately. 
Transmucosal  drug  delivery  systems  can  be  bi-directional  or  unidirectional.  Bi-
directional  (Figure  1)  patches  release  drug  in  both  the  mucosa  and  the  mouth  while,
Unidirectional (Figure 2) patches release the drug only into the mucosa. 
FIG 3 : Buccal Patch  designed for Bidirectional drug release 
FIG 4: Buccal Patch designed for unidirectional drug release 
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1.7.1. Solid buccal adhesive dosage forms 10
They  are  dry  formulations  which  achieve  bioadhesion  via  dehydration  of  the  local
mucosal surface.
(a). Buccal Tablets 
Tablets  have  been  the  most  commonly  investigated  dosage  forms  for  buccal  drug
delivery.  Several  bioadhesive  buccal  tablet  formulations  have  been  developed  by  direct
compression method in recent years either for local or systemic drug delivery. They are designed
to release the drug either unidirectionally by targeting buccal mucosa or multi- directionally into
the saliva. Alternatively, the dosage form can contain an impermeable backing layer to ensure
that drug is delivered unidirectionally. A typical bioadhesive formulation of this type consists of
a  bioadhesive  polymer  (such  as  polyacrylic  acids  or  a  cellulose  derivative),  alone  or  in
combination, incorporated into a matrix containing the active agent and excipients, and perhaps a
second impermeable layer to allow unidirectional drug delivery.
(b). Bioadhesive Micro/nanoparticles 
Bioadhesive micro/nanoparticles offer the same advantages as tablets but their physical
properties enable them to make intimate contact with a lager mucosal surface area. These are
typically delivered as an aqueous suspension or are incorporated into a paste or ointment or
applied in the form of aerosols. Particulates have the advantage of being relatively small and
more likely to be acceptable by the patients. Bioadhesive polymeric microparticles of carbopol,
polycarbophil, chitosan or Gantrez are to adhere to porcine esophageal mucosa, with particles
prepared  from the  polyacrylic  acids  exhibiting  greater  mucoadhesive  strength  during  tensile
testing studies. However in elution studies, particles of chitosan or Gantrez were found to persist
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on  mucosal  tissue  for  longer  periods  of  time.  Moreover,  the  absolute  bioavailability  of
microsphere formulations was higher than that of reference tablets in spite of a lower drug dose.
Liposomes are one of the alternatives  for  drugs  which are poorly soluble and hence are not
efficiently delivered from a solid dosage form. For example, silamyrin liposomal buccal delivery
showed steady state permeation through a chicken buccal pouch for 6 hrs and which was higher
than free drug powder.
(c). Bioadhesive Wafers 
The  delivery  system  is  a  composite  wafer  with  surface  layers  possessing  adhesive
properties,  while the bulk layer  consists of antimicrobial  agents,  biodegradable polymers and
matrix polymers. 
(d). Bioadhesive Lozenges 
A slow release bioadhesive lozenge offers the potential for prolonged drug release with
improved patient compliance. Bioadhesive lozenges may be used for the delivery of drugs that
act within the mouth including antimicrobials, corticosteroids, local anaesthetics, antibiotics and
antifungals. A Bioadhesive lozenge has been reported as a means to deliver antifungal agents to
the oral cavity. The limitation of these bioadhesive lozenges  is the short residence time at the
site of absorption which depends to the size and type of formulation and since dissolve within
30min,  the  total  amount  of  the  drug  that  can  be  delivered  is  limited.  The  dissolution  or
disintegration of lozenges is usually controlled by the patient, i.e. how hard they suck the unit.
Increased sucking and saliva production causes uncontrolled swallowing and loss of drug down
the GI tract. 
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1.7.2.Semi-solid dosage forms 
(a). Medicated chewing gums 
Although medicated chewing gums pose difficulties in regulation of the administered
dose, they still have some advantages as drug delivery devices, particularly in the treatment of
diseases of the oral cavity and in nicotine replacement therapy. Some commercial products are
available  in  the  market.  Caffeine  chewing  gum,  Stay  Alert,  was  developed  recently  for
alleviation of sleepiness. It  is absorbed at a significantly faster rate and its bioavailability was
comparable to the capsule formulation. Nicotine chewing gums (e.g.,  Nicolette and Nicotine)
have been marketed for smoking cessation.
(b). Adhesive Gels 
Various adhesive gels may be used to deliver drugs  via the buccal  mucosa and allow
sustained release. Gel forming bioadhesive polymers include cross- linked polyacrylic acid that
has  been  used  to  adhere  to  the  mucosal  surfaces  for  extended  periods  of  time and  provide
controlled  release  of  drug at  the site  of  absorption.  The  limitations for  gel  formulations are
inability to deliver a measured dose of drug to the site and as a result have limited uses for drugs
with narrow therapeutic window.
(c). Buccal patches/films 
Patches  are  laminates  consisting of  an  impermeable  backing  layer,  a  drug-containing
reservoir layer from which the drug is released in a controlled manner, and a bioadhesive surface
for mucosal attachment. Flexible films/patches have been prepared either by solvent casting or
hot melt  extrusion technique to deliver drugs  directly to a mucosal  membrane.  Compared to
creams and ointments they offer advantages in delivering a measured dose of drug to the site.
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1.7.3. Liquid dosage forms 
They are solutions or suspensions of drugs in suitable aqueous vehicles. Such types of
dosage  forms  are  usually  employed  to  exert  local  action  into  the  oral  cavity  and  several
antibacterial mouthwashes and mouth-freshener are commercially available for this purpose. The
limitation associated with these liquid dosage forms are that  they are not  readily retained or
targeted to buccal mucosa and can deliver relatively uncontrolled amounts of drug throughout
oral cavity. From the wide range of polymer solutions, chitosan represents the greatest binding,
followed by methylcellulose, gelatin, carbopol and polycarbophil. Viscous liquids may be used
to coat buccal surface either as protectants or as drug delivery vehicles to the mucosal surface.
Dry mouth is  treated with artificial  saliva solutions that  are retained on mucosal  surfaces  to
provide lubrication. These solutions contain sodium CMC as bioadhesive polymer.
Recent developments in buccal drug delivery systems
1.  Biobadhesive Spray
Buccoadhesive  sprays  are  gaining  popularity  over  other  dosage  forms  because  of
flexibility, comfort, high surface area and availability of drug in  solution form. The fentanyl
Oralet  is the first FDA-approved formulation developed to take advantage of oral transmucosal
absorption for the painless administration of an opioid in a formulation acceptable to children.
The  FDA  approved  Subutex  (buprenorphine)  for  initiating  treatment  of  opioid
dependence (addiction to opioid drugs, including heroin and opioid analgesics) and Suboxone
(buprenorphine and naloxone) for continuing treatment of addicts. In 2005, Oral-lyn buccal spray
was approved for commercial marketing and sales in Ecuador.
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2.  Gel Forming Liquids: 
This type of a formulation is liquid upon instillation and undergoes a phase transition to
form  a  viscoelastic  gel  in  response  to  stimulus  such  as  temperature,  ionic  strength  or  pH.
Carbomers become more viscous upon increased pH. Poloxamers and smart hydrogel ( Adnaced
medical solution) gel at approximately body temperature.
Gellan  gum  and  alginate  both  form  gel  in  response  to  increased  ionic  strength
(particularly with Ca+2  ions). Gel forming formulations are currently used for sustained ocular
delivery. Recent work has examined the oesophageal retention of smart Hydrogel, a liquid that
gels in response to both high force and temperature, with its gelling temperature at about 32°C.
For the delivery Recent developments in buccal drug delivery systems, such as lipophilic
gel, buccal spray and phospholipid vesicles have been recently proposed to deliver peptides via
the  buccal  route.  In  particular,  some  authors  proposed  the  use  of  cubic  and  lamellar  liquid
crystalline phases of glyceryl monooleate as buccal drug carrier for peptide drugs. A novel liquid
aerosol  formulation  (Oralin,  Generex  Biotec)  has  been  developed  recently.  Phospholipid
deformable  vesicles, transfersomes, have been recently devised of insulin in the buccal cvaity.
1.8. Evaluation of Buccal Delivery Systems11
Buccal adhesive drug delivery devices are subjected to the routine evaluation tests such
as  weight  variation,  thickness  variation,  friability,  hardness,  content  uniformity,  invitro
dissolution for tablets; tensile strength, film endurance, hygroscopicity etc. for films and patches;
viscosity,  effect  of  aging  etc.  for  gels  and  ointments.  They  should  also  to  be  evaluated
specifically for their bioadhesive strengths and permeabilities.
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1.8.1. Moisture absorption studies for buccal patches 
The  moisture  absorption  studies  for  the  buccal  patches  give  an  indication  about  the
relative  moisture  absorption  capacities  of  polymers  and an  idea  whether  the  buccal  patches
maintain  their  integrity  after  absorption  of  moisture.  Moisture  absorption  studies  have  been
performed in 5 % w/v agar in distilled water, which while hot was transferred to  plates and
allowed to solidify. Then six buccal patches from each formulation were selected and weighed.
Buccal patches were placed in desiccators overnight prior to the study to remove moisture if any
and laminated on one side with water impermeable backing membrane. Placed on the surface of
the agar plate and incubated at 37° C for 2 hrs in incubator. 
Swelling and erosion studies for buccal tablets 
Swelling  and  erosion  studies  for  buccal  tablets  were  determined  gravimetrically  in
phosphate buffer, of pH 6.6. The tablets were attached to pre-weighed glass supports using a
cyanoacrylate  adhesive  sealant.  The supports  with tablets  were  immersed into the  phosphate
buffer at 37 °C. At pre- determined time intervals, the devices were removed from the media,
blotted with tissue paper to remove excess water, and weighed. After determination of the wet
weight, the tablets were dried at 40°C until constant mass. 
Study of the surface pH 
The bioadhesive buccal tablets were covered with 1ml of distilled water and allowed to
swell for 1-2h at room temperature. The surface pH of the tablets or patches was measured by
bringing the pH meter electrode in contact with the surface of the patch or tablet and allowing it
to equilibrate for one minute.
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Bioadhesion measurement 
Methods available for the measurement of bioadhesion are limited, and their selections
depend on applicability, reproducibility, and providing useful information. It is unnecessary to
compare the absolute values of different methods and is more meaningful to examine the relative
bioadhesive  performance  using  each  technique.  In  addition,  some  factors,  including  saliva
secretion, mastication, and mucus turnover that can markedly affect the adhesion strength and
duration of in vivo adhesion are not present in invitro testing.
Determination of the residence time 
Ex vivo residence time12
Ex vivo residence time was determined using a modified USP disintegration apparatus by
taking the disintegration medium composed of 800 ml phosphate buffer of pH 6.8 maintained at
37 °C. The porcine buccal tissue was tied to the surface of a glass slab, vertically attached to the
apparatus. The time which was taken for complete erosion or detachment of the tablet from the
mucosal surface was recorded and considered as ex vivo residence time.
In vivo residence time13 
The experiment was performed in eight healthy adult male volunteers, aged between 22
and 28 years.  The volunteers  were asked to record the residence time of the film on buccal
mucosa in the oral cavity, which was taken as the time for the patch to dislodge completely from
the buccal mucosa by continual sensation of the patch as well as the backing membrane. In vivo
residence time was recorded in each case.  
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Permeation studies 
Buccal absorption/permeation studies must be conducted to determine the feasibility of
this route of administration for a drug candidate and to determine the type of enhancer and its
concentration which were to control the rate of permeation of drugs during the pre-formulation
studies. Similar to an in vitro permeation study in transdermal drug delivery, different types of
diffusion cells with certain modifications are suitable to conduct permeation studies, except that
the  buccal  mucosa  dissected  from  model  animals  are  used  as  diffusion  barriers  for  buccal
delivery.  These studies involve methods that  would examine  in vitro,  ex vivo and/or in vivo
buccal permeation profile and kinetics of absorption of the drug. 
Buccal absorption test 
Measure the kinetics of the drug absorption by swirl  a 25 ml sample of the test solution
for 15 min by human volunteers followed by the expulsion of the solution. The amount of the
drug remaining in the expelled volume is then determined to assess the amount of drug absorbed.
The drawbacks of this method are inability to localize the drug solution within a specific site of
the  oral  cavity,  accidental  swallowing  of  a  portion  of  the  sample  solution  and  the  salivary
dilution of the drug.
Modified Beckett's test 
The test has been modified by addition of phenol red as a marker for drug dilution by saliva
secretion as well as for accidental swallowing of the drug solution. The ‘Schumann and Turner
Test’ has also been modified by taking a small sample of the solution in the oral cavity every few
minutes, without removal of the residual solution. In this way he was able to study kinetics of the
absorption in a single test for 15–20 minutes. Advantages of this type of test over the original
absorption test are; corrections for saliva secretion, accidental swallowing and changes in pH can
be made and that a complete absorption curve can be measured in one single test. 
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Parthasarathy Govindasamy14 et al., (2013) prepared Buccal patches of  carbamazepine
with  unidirectional  drug  release  were  HPMC,  polyvinyl  alcohol,polyvinyl  yrrolidone,ethyl
cellulose by solvent casting method.water impermeable layer of patches provide unidirectional
drug  release.They  were  evaluated  for  thickness,mass   uniformity,surface  pH,and  floading
endurance.  The  formulation  were  evaluated  further  for  swelling  studies,exvivomucoadhesive
strength,exvivo  mucoadhesion time,invitro  drug release,exvivo  permeation, accelerated stability
studies  and  FTIR  and  XRD spectral  studies.  The  prepared  unidirectional  buccal  patches  of
carbamazepine provided a maximum drug release within specified mucoadhesive period and it
indicate a potential alternative drug delivery system for systemic delivery of carbamazepine.
Sarath chandran C 15 et al., (2013)  investigated the ability of polymer to release the
Bisoprolol fumarate in a controlled pre determined manner. The mucoadhesive buccal patches
were prepared by solvent casting method with appropriate modification. The prepared patches
were subjected to physical evaluations, invitro diffusion , and stability study. The result obtained
was satisfactory with all the formulation, but, the patches prepared with 2% chitosan showed a
better invitro diffusion result as it can diffuse 96% of drug within 12 h of the therapy. The result
of physical evaluation and stability study indicating that the Bisoprolol buccal patches with 2%
chitosan could effectively treat the possible anginal attack and hypertension.
Swati c. et16 al.,(2013) showed that the solubility and dissolution rate of Ramipril were
significantly  improved  by  complexation  with  β-cyclodextrin  and  Hydroxy  propyl
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βcyclodextrin with respect to drug alone. The kneaded complex showed higher dissolution rate
than other complex and it was incorporated into buccal Patches. The patches were prepared by
solvent casting method using hydroxyl propyl methyl cellulose (HPMC K15) and Poloxomer.
The patches were found to be smooth in appearance, uniform in thickness, weight uniformity,
drug content, swelling index, folding endurance,  surface pH and  invitro  diffusion study using
Keshery chien diffusion cell. The Patch of 0.5% HPMC K15 exhibit  invitro release of 81.16%
through cellophane membrane and 75.72% release through egg membrane and the Patch of 0.5%
Poloxomer exhibit invitro release of 77.24% through cellophane membrane and 71.08% release
through egg membrane in 8 h showing good mucoadhesive strength and mucoadhesive time. The
Optimized patch was subjected to  exvivo  studies through goat buccal mucosa showed 63.49%
release in 8 h.
N.G. Raghavendra Rao and Keyur Patel17et al., (2013) developed and optimized  the
formulations  of  mucoadhesive patches  of Ropinirole.  Ropinirole buccal  patches  are prepared
using  different  mucoadhesive  polymers  by  solvent  casting  technique.  Buccal  patches  were
characterized  for  parameters  like  physical  appearance  and  surface  texture,  mass  uniformity,
thickness,  folding  endurance,  swelling  index,  surface  pH,  drug  content  uniformity,  invitro
residence time, Bursting strength,  exvivo  mucoadhesive force,  exvivo permeation study,  invitro
drug release study and drug-excipients interaction study. Release of Ropinirole from all patches
followed zero order and mechanism was diffusion rate limited. Ropinirole mucoadhesive buccal
patches  promising one as the controlled drug delivery,  shows moderate swelling,  convenient
resident time will lead to improve the bioavailability and greater therapeutic efficacy.
Sellappan  Velmurugan  ,  P.Srinivas18et  al., (2013)   prepared  mucoadhesive  buccal
tablets of Losartan potassium and evaluated for physicochemical parameters such as hardness,
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thickness uniformity, weight variation, and surface pH and moisture absorption studies.exvivo
mucoadhesive strength, exvivo residence time and invitro release studies showed that formulation
containing 1:1.25 ratio of drug and polymer combination showed satisfactory bioadhesive and
exhibited optimum drug release (91.33 % after 12h). The  bioadhesive buccal tablets with desired
permeability could be prepared. The Stability of Losartan potassium mucoadhesive buccal tablets
was determined in natural human saliva; it was found that both Losartan potassium and buccal
tablets were stable in human saliva.
Vandana Soni & Aviral Jai19et al., (2013) developed a controlled release drug delivery
device  of  Glipizide  to  maintain  its  bioavailability  over  an  extended  period  of  time  and  to
circumvent the hepatic first pass effect. Drugcoat and HPMC were used as a polymer for the
preparation  primary  and  secondary  layer  respectively,  of  controlled  release  bilayerd
buccoadhesive patches of drug.  The prepared patches  were evaluated for  various  invitro  and
invivostudies. The developed bilayered buccoadhesive delivery system bears potential to deliver
the drug in a controlled manner over an extended period of time.
Nagaveni Somepalli20 et al.,(2013) prepared Salbutamol sulfate patches  HPMC, SCMC
and Carbopol  934 in  various  proportions  and  combinations  using Glycerol  and  tween-80  as
plasticizers. Patches were laminated on one side with a water impermeable backing layer using
ethyl cellulose for unidirectional drug release. The thickness of medicated patches were ranged
between 0.402 and 0.431 mm and mass varied between 0.0312 and 0.0352 g. The surface-pH of
patches  ranged  between  6  and  7.  All  formulations  showed  good  folding  endurance.  The
maximum  invitro  release was found to be 93.89% over a period of 150 min. Data of  invitro
release from patches were fitted to different  kinetic models such as Higuchi and Korsmeyer–
Peppas models to explain the release profile. 
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B.Samyuktha Rani21 et al., (2013) fabricated Venlafaxine HCL patches were by using
sodium alginate with various polymers such as CMC, HPMC E15 in various proportions using
solvent  casting  technique.  Buccal  patches  were  evaluated  by  different  parameters  such  as
thickness, weight uniformity, content uniformity, swelling index, surface pH, moisture up take
study, moisture absorbance study, folding endurance and  invitro  drug release study and FTIR
studies. The optimized fabricated patches showed that the drug release indicates non- fickian
release kinetics and diffusion as chain relaxation mechanism. All the fabricated patches were
effective and showed excellent sustained drug release for 8h.
J. Ravi Kumar Reddy22 et al., (2013) fabricated Tapentadol hydrochloride buccal films
by  solvent  casting  technique  with  different  polymer  combinations  of  hydroxypropyl
methylcellulose, chitosan, carbopol and carbopol. Drug–polymer interaction studies by Fourier
transform infrared spectroscopy showed that there was no significant interaction between drug
and polymers.  Stability study of  buccal  films was performed in natural  human saliva.exvivo
permeation studies were conducted using fresh sheep buccal mucosa and buccoadhesive strength
was  calculated  by  modified  balance  method  and  showed  sufficient  strength  in  all  the
formulations. Good correlation was observed between the  invitro  drug release and  invivodrug
release,  with  a  correlation  coefficient  of  0.996.  Drug  diffusion  from  buccal  films  showed
apparently zero order kinetics and release mechanism was diffusion controlled after considerable
swelling.
Rama devi Bhimavarapu  23et al., (2013)  formulated mucoadhesive buccal patches of
sertraline hydrochloride inorder to bypass the first pass metabolism. The prepared patches were
evaluated for their weight variation, thickness, folding endurance, surface pH, swelling index,
moisture uptake study,  moisture absorbance study,  drug content uniformity and  in vitro  drug
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release  and  FTIR  studies  were  conducted  for  Drug  –  Excipient  compatibility  testing.  The
optimized  patches  showed  that  the  drug  release  indicates  non-  fickian  release  kinetics  and
diffusion as chain relaxation mechanism. Formulation  showed the highest release rate of 83.41%
and all the prepared patches were effective and showed excellent sustained drug release.
Iswarya Sridhar24 et  al.,  (2013)  optimized the formulations of  mucoadhesive buccal
patches of Ondansetron hydrochloride. The patches of all formulations showed good flexibility,
mucoadhesive strength and smooth surface and were found to be stable. Drug content was found
to be uniform in all the formulations and all the evaluation parameters were found to be within
acceptable limits. The patches showed sustained release for a period of 8 h thereby achieving
therapeutic efficacy and good patient compliance. The optimized patches were found to be stable
when exposed to accelerated stability conditions.
Rama bukka25et al., (2012)   formulated  a buccal dosage form of Felodipine to increase
its bioavailability by casting method using Polyethylene Oxide with hydroxy propyl cellulose
(HPC)  or  Ethyl  Cellulose  using  23  factorial  design.  The  solvent  was  ethanol  and
dichloromethane  (1:1 ratio).  The films were evaluated for  exvivo  mucoadhesive  strength and
invitro residence time, drug release and percentage swelling. The best set of formulation was F2,
as  per  result  of  bioadhesive  strength,  invitro residence  time  which  is  having  highest
concentration of Polyethylene Oxide (0.1%) & HPC (2.5%). All the formulations were following
the zero order release and non Fickian model of kinetic release.
M.Jyostna, Bhaskar Reddy26 et al., (2012) prepared Buccal patches of Desloratidine by
solvent evaporation method using HPMC 15 cps and xanthan gum which are the hydrophilic
polymers  in  different  ratios.  The  prepared  patches  were  tested  for  physical  parameters  like
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Thickness, Folding endurance, Uniformity of weight, swelling index and Surface pH of patches
and  invitro  drug release studies.  All the physical  parameters  fall  within the limits.  The drug
content was uniform in all the formulated buccal patches of Desloratidine. The results indicate
uniform distribution of drug within the patches. The release of Desloratidine from the buccal
patch  was  sustained  up  to  6h.Among the  five  formulations,  the  F-V shows  maximum drug
release of 89.03% in 6 h. The optimized formulation follows zero order kinetics to release the
drug from the patches.
N. G. Raghavendra Rao27 et al., (2012) prepared buccal patches of zolmitriptan using
hydroxy propyl methyl cellulose (HPMC). HPMC and gel forming polymers like HPMC (K4M),
carbopol,  poly vinyl  pyrrolidone and Eudragit  RL-100 by Solvent Casting technique.  All the
prepared  patches  were  smooth  surface  and  elegant  texture.  From  among  all  the  developed
formulations,  the  formulation  containing  HPMC  K4M  and  carbopol  934  retarded  the  drug
release in a controlled manner for prolonged period of more than 8 h, gave satisfactory invitro
resident time maximum duration of 7.46 h, so it was selected as the best formulation. Swelling
studies indicated significant water uptake and contributed in drug release. Stability studies were
as  per  ICH guidelines,  suggesting  that  there  was  no  significant  change  in  surface  pH,  drug
content, bioadhesion property, swelling behavior of the patches. FTIR studies revealed that, there
was no incompatibility of the drug with the excipients used.
Jobin Jose28 et  al.,(2012) developed the mucoadhesive buccal  patch of  labetalol  and
systematically evaluate invitro performances of buccal films of labetalol hydrochloride by using
chitosan, CARBOPOL K30, CARBOPOL K90, HPMC and polyethylene glycol (PEG) 1000 as
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plasticizer. Buccal films were developed by solvent casting technique and all the formulations
were  examined  for  patch  thickness,  weight  variation,  drug  content,  surface  pH,  folding
endurance,  invitro  residence  time and  invitro  release.  The  all  prepared  buccal  patches  were
transparent, smooth, consistent  and flexible.  The surface pH of all formulation showed to be
neutral. It was found that formulations showed good swelling, a convenient residence time, as
well as promising drug release pattern and the release of the drug from the patches followed the
diffusion controlled mechanism in all the formulations. Journ
Bharath Kumar.V29et  al., (2011) prepared and evaluated mucoadhesive buccal  films
containing  Diltiazem hydrochloride by employing HPMC, eudragit, ethyl cellulose alone and in
combination  with  CARBOPOL.  The  prepared  mucoadhesive  buccal  films  showed  uniform
thickness, weight,  folding endurance,  surface pH, drug content and swelling index. The drug
content of all the formulation was found to be uniform. invitro drug release studies indicated that
the films prepared with HPMC (3%) and ethyl cellulose (4%) has shown fast and slow release
respectively. The formulated films were stable during stability studies at 45ºC and 75%RH with
respect to drug content.
Santosh Kumar30 et al.,( 2011) formulated mucoadhesive buccal patches of flurbiprofen
(FBN) in order  to enhance  solubility.  Solubity enhancement  was attempted by making solid
dispersion of drug with β-CD (cyclodextrin).. Buccal patches were prepared by solvent casting
technique  using  polymers  like  polyvinyl  alcohol  (PVA),  sodium  carboxymethyl  cellulose
(SCMC), and hydroxypropyl methylcellulose (HPMC). The prepared patches were evaluated for
their weight variation, thickness, folding endurance, surface pH, swelling index,invitro residence
time,invitro permeation studies, drug content uniformity and bioadhesion test.
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Marina  Koland31 et  al., (2010)  Buccal  delivery  is  considered  to  be  an  important
alternative to the peroral route for the systemic administration of  drugs. Losartan potassium is an
angiotensin II receptor antagonist with an oral bioavailability of only 33% due to extensive first
pass  metabolism.  Mucoadhesive  buccal  films  of  losartan  potassium  were  prepared  using
hydroxypropyl methyl cellulose (HPMC) and retardant polymers ethyl cellulose (EC) or eudragit
RS 100. Films were flexible and those formulated from EC were smooth whereas those prepared
from Eudragit were slightly rough in texture. The mucoadhesive force, swelling index, tensile
strength and percentage elongation at break was higher for those formulations containing higher
percentage of HPMC. invitro drug release studies reveal that all films exhibited sustained release
in the range of 90.10 to 97.40 % for a period of 6 h. The data was subjected to kinetic analysis
which indicated non fickian diffusion for all formulations except E2.exvivo  permeation studies
through  porcine  buccal  mucosa  indicate  that  films  containing  higher  percentage  of  the
mucoadhesive polymer HPMC showed slower permeation of the drug for 6-7 h.
Bingi Manasa32 et  al.,(2010) developed Resperidone patches  using HPMC (15 & 47
cps), chitoson, poly vinyl alcohol, poly vinyl pyrilodine. The patches were evaluated for their
thickness,  Uniformity content,  folding  endurance,  weight  uniformity,  Swelling  index,  tensile
strength  and  surface  pH.invitro  loaded  studies  of  resperidone-loaded  patches  in  phosphate
buffer(pH 6.6) exhibited drug release in the range of 67.32% to 98.28 in 60 min. Data of invitro
release from patches were fit in to different equations and kinetic models to explain kinetics. The
invitro release study showed that patches  could deliver drug to the oral  mucosa.  The results
indicate that the mucoadhesive buccal patches of resperidone may be good choice to bypass the
extensive hepatic first pass metabolism with an improvement in the bioavailability of resperidone
through buccal mucosa.
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S.Velmurugan, B.Deepika33 et al.,(2010) prepared Buccoadhesive tablets of piroxicam
by using HPMC K4M and carbopol  934 as  mucoadhesive  polymers.  The formulations  were
tested for  invitro  drug release,  bioadhesive strength,  moisture absorption,  residence time and
drug  permeation  through  porcine  buccal  mucosa.  Optimized  formulation  showed  maximum
release  of  the  drug  (97.67±0.41)  with  the  peppas  model  release  profile  and  permeated
26.52±0.19  of  the  drug  through  porcine  buccal  membrane.  The  suitable  bioadhesive  buccal
tablets with desired permeability could be prepared. Stability of piroxicam buccal tablets was
determined in natural human saliva; it was found that both piroxicam and buccal tablets were
stable in human saliva.
Bhanja  Satyabrata34 et  al.,(2010) designed  and  evaluated  mucoadhesive  bilayered
buccal  devices  comprising  of  a  methotrexate  containing  mucoadhesive  layer  and  drug  free
backing  membrane.  sodium  alginate  alone  or  in  combination  with  sodium  carboxy  methyl
cellulose, polyvinyl pyrollidine and carbopol 934 and backing membrane (ethyl cellulose). The
patches were fabricated by solvent casting technique and evaluated for film weight uniformity,
thickness, swelling index, surface pH, mucoadhesive strength, mucoadhesive time and folding
endurance, invitro and exvivo drug release. A combination of sodium alginate with carbopol 934
and glycerol  as  plasticizer  gave  promising results.  The  optimum patches  exhibits  an  invitro
release of 82% through cellophane membrane and 70.78% in 8 h through buccal mucosa with
satisfactory,  mucoadhesive  strength  mucoadhesive  time.  The  invitro  release  kinetics  through
cellophane membrane fits  well  for Higuchi,  while  exvivo  through buccal  mucosa it  followed
zero-order  kinetics.  The  exvivo  data  also  fitted  to  Korsmeyer-Peppas  equation  which
characterizes  the  release  mechanism  as  non-Fickian,  which  means  the  drug  release  is
independent of concentration gradients.
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Satyabrata Bhanja35 et al.,(2010) formulated and evaluated mucoadhesive buccal tablets
of Timolol maleate to circumvent the first pass effect and to improve its bioavailability with
reduction in dosing frequency and dose related side effects. The tablets were prepared by direct
compression method. The best  invitro  drug release profile was achieved with the formulation
contains the drug, Carbopol 934p and HPMC K4M in the ratio of 1:2.5:10. The invitro release
kinetics  studies  reveal  that  all  formulations  fits  well  with  zero  order  kinetics  followed  by
Korsmeyer-Peppas, first order and then Higuchi’s model and the mechanism of drug release is
non-Fickian diffusion.
Subhash V. Deshmane36 et al.,(2009) developed verapamil hydrochloride buccal patch
to increase bioavailability and prevent first pass metabolism of drug The mucoadhesive strength,
vapour transmission and invitro released of water soluble drug through water insoluble chitosan
base matrix were found satisfactorily. The physical appearance of buccal patch was examined by
scanning electron microscopy. The released kinetic model best to fit for the optimized batch was
Hixson Crowell, indicating that the drug release from systems in which there is a change in the
surface area and the diameter of particles present in dosage form.
Gazzi  Shankar37 et  al.,  (2009)21 formulated and  evaluated  bioadhesive  buccal  drug
delivery of tizanidine hydrochloride tablets prepared by direct compression using bioadhesive
polymers such as hydroxypropyl  methyl cellulose K4M, sodium carboxymethyl  cellulose and
combination of these two polymers.  In  order to improve permeation of drug,  the permeation
enhancers  like  beta-cyclodextrin  (β-CD),  hydoxypropyl  beta-cyclodextrin  (HP-β-CD),  and
sodium deoxycholate  (SDC) were  added  to  the formulations.  The  β-CD and HP-β-CD were
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taken in 1:1 molar ratio.  invitro  release of optimized batch was found to be non-Fickian. The
stability  studies  in  natural  saliva  indicated  that  optimized  formulation  has  good  stability  in
human saliva. 
Deelip Derle38et al.,  (2009) formulated and evaluated buccoadhesive bi-layer  tablet of
propranolol hydrochloride using a buccoadhesive polymers such as sodium alginate and carbopol
971 P along with ethyl cellulose as an impermeable backing layer. Tablets containing sodium
alginate and carbopol 971 P in the ratio of 5:1 showed the maximum percentage of invitro drug
release without disintegration in 12 h. The swelling index was proportional to sodium alginate
content and inversely proportional to carbopol 971 P content. The surface pH of all tablets was
found to  be  satisfactory,  close  to  neutral  pH;  hence,  no  irritation  would observe  with  these
tablets. The mechanism of drug release was found to be zero-order kinetics.
V.N.  Deshmukh39 et  al., (2009) formulated  and  evaluated  theophylline  anhydrous
bioadhesive  tablets.  Different  types  of  natural  hydrophilic  polymers  such  as  xanthium gum,
locust gum, guar gum, karaya gum and their combinations were used to formulate matrix tablets.
The combination of karaya gum:guar gum (6:4) tablet showed a greater boiadhesive strength as
compared with a single gum and other gum combination tablets. Karaya gum:guar gum were not
discharged from the mucus membrane and were dissolved in the gastric fluid. An increase in
gum concentration increases the drug release profile beyond 12 h whereas there is no significant
effect of gum concentration on the bioadhesive strength of the tablet.
Monica rao40et al.,  (2009)  evaluated effervescent floating matrix tablet formulations of
salbutamol  sulphate.  Two  viscosity  grades  of  HPMC  as  matrix  materials  were  used  for
formulating  the  tablets,  which  are  prepared  by  wet  granulation.  The  invitro drug  release
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mechanism showed anomalous transport.  An increase in polymer  concentration and viscosity
grade of the polymer resulted in a decrease in the release rate.
  R Manivannan, A Balasubramaniam41 et al.,(2008) fabricated Mucoadhesive buccal
tablets  of  Diltiazem  hydrochloride  using  carbopol-934,  Sodium  carboxy  methyl  cellulose
(SCMC),  Hydroxy  propyl  methyl  cellulose  (HPMC),  sodium  alginate  and  guar-gum  as
mucoadhesive polymers. The carbopol-934 is used as a primary polymer because of its excellent
mucoadhesive property and secondary polymers like HPMC, SCMC, sodium alginate and guar-
gum  were  used.  The  effect  of  secondary  polymer  loading  on  drug  release  was  studied.
Formulation follows zero  order  drug release.  FTIR  studies  show no evidence  on interaction
between drug and polymers. 
  R Manivannan42 et al., (2008) formulated and evaluated mucoadhesive buccal tablets of
diltiazem hydrochloride using cabopol-934, sodium carbpxy methyl cellulose (SCMC), Hydroxy
propyl  methyl  cellulose (HPMC),  sodium alginate and guar-gum as mucoadhesive polymers.
eight formulations were developed with varying concentration of polymers. The carbopol-934 is
used  as  primary  polymer  because  of  its  excellent  mucoadhesive  property  and  secondary
polymers like HPMC, SCMC, sodium alginate and guar-gum were used. The effect of secondary
polymers loading on drug release was studied. Formulations F2 showed maximum release of
76.98% in 8 h. Formulation F2 showed maximum swelling index of 3.7 after 8 h. Formulation
FA2 follows zero order drug release.  FTIR studies show no evidence on interaction between
drug and polymers. The release indicates that suitable mucoadhesive buccal tablets with desired
properties could be prepared.
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Emami  J  43 et  al.,  (2008) developed  and  evaluated  controlled-release  buccoadhesive
verapamil  hydrochloride  tablets,  to  study controlled  release  buccoadhesive  tablets  inorder  to
achieve  constant  plasma  concentrations,  to  improve  the  bioavailability  by  the  avoidance  of
hepatic first-pass metabolism and to prevent frequent administration. The maximum bioadhesive
strength was observed in tablets formulated with a combination of CP-NaCMC followed by CP-
HPMC and NaCMC-HPMC. Decreasing the content of CP in CP-HPMC tablets or NaCMC in
CP-NaCMC or NaCMC-HPMC systems resulted in decrease in detachment forces. 
Ganesh  P44 et  al.,  (2008)  developed  and  evaluated  mucoadhesive  buccal  tablets  of
domperidone.  The  mucoadhesive  polymers  used  in  the  formulations  were  Carbopol  934P,
Methocel K4M, Methocel E15LV and Chitosan. Tablets were prepared by direct compression
method using polymers in different ratios. The best mucoadhesive performance and invitro drug
release profile were exhibited by the tablets containing chitosan and Methocel K4M in ratio of
1:1. It was observed that optimized batch follows Hixon Crowel release kinetics.  
M. Nappinai,45et  al.,(2008) formulated  and  evaluated  nitrendepine  buccal  film  using
mucoadhesive polymers  like HPMC K100, hydoxypropylcellulose,  NaCMC, sodium alginate,
polyvinyl alcohol, PVP K30 and Carbopol 934P. Based on the evaluation of these result it was
concluded  that  buccal  film  made  of  hydroxypropylcellulose  and  NaCMC  which  showed
moderate drug release and satisfactory film characterization could be selected as the best among
formulation studies.
J.Ali46et al.,(2008)  prepared chronomodulated drug delivery of salbutamol sulphate for
the treatment of nocturnal asthma. The core containing salbutamol sulphate were prepared by
direct compression method using different ratios of microcrystalline cellulose and effervescent
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agent  and  then  coated  sequentially  with  an  inner  swelling  layer  containing  hydrocolloid,
hydroxypropyl methyl cellulose  and an outer rupturable layer having Eudragit RL/RS (1:1). The
rupture and dissolution test were studied using the USP paddle method at 50 rpm in 0.1 N HCl
and phosphate buffer pH 6.8. The lag time of drug release decreased by increasing the inner
swelling layer and increased by increasing the rupturing layer level.
F.K. Alanazi1 47et al., (2007) ; formulated Ketorolac tromethamine buccoadhesive films
to overcome the limitations in the currently available dosage and routes of administration which
in  sequence  will  increase  patients  compliance.  Films  were  cast  from  organic  and  aqueous
solvents  using  various  bioadhesive  polymers  namely:  sodium carboxymethyl  cellulose  (Na-
CMC), hydroxypropyl cellulose (HPC), hydroxypropylmethyl cellulose (HPMC) and Carbopol
934. Formulation containing carbopol 0.5% and HPMC 0.5% was found to be the best film as it
shows good adhesion, acceptable pH, and gives a reasonable ketrolac release (about 85-90% at 6
h). In addition, this film was subjected to Invitro and invivo release. The obtained results indicate
that  the concentration of ketorolac in the oral  cavity was maintained above 4.0 µg/mL for  a
period of at least 6 h. This film shows promising results for using the ketrolac buccoadhesive
route of administration topically and systemically. 
Vamshi  Vishnu  Yamsani48 et  al.,  (2007) developed  and  evaluated  buccoadhesive
carvedilol  tablets,  using  HPMC  K4M,  HPMC  K15M  and  carbopol  934  as  mucoadhesive
polymers. Formulations of the BC or BD series were composed of HPMC K4M or HPMC K15M
in rations of 1:1 to 1:5 whereas in the BE series, Carbopol 934 was used (1:0.25 to 1:1.50).
Formulation BC3 showed maximum release of the drug (88.7 ± 0.4%) with the Higuchi model
release profile and permeated 21.5 ± 2.9% of the drug (flux 8.35 ± 0.291 µg h-1 cm-2) permeation
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coefficient 1.34 ± 0.05cm h-1) through porcine buccal membrane. BC3 formulation showed 1.62 ±
0.15 N of peak detachment force and 0.24 ± 0.11 ml of work of adhesion
P.D.Nakhat 49et al.,(2007) studied on buccoadhesive tablets of terbutaline sulphate  prepared by
direct compression method using bioadhesive polymers like Caebopol 934P , Methocel K4M,
Methocel  K15M and  sodium carboxy methyl  cellulose  either  alone  or  in  combination  with
baking layer  of  ethyl  cellulose.  The  maximum boiadhesive strength  was  observed  in  tablets
formulated with Carbopol 934P alone and strength decreases with decrease in its contents. The
tablets  were  evaluated  for  invitro release  in  pH  6.8  phosphate  buffer  for  10  h  using  a
standardized  dissolution apparatus.  In  order  to  determine  the  mode of  release,  the  data  was
subjected to Korsmeyer and Peppas diffusion model. All the formulations followed non-Fickian
release mechanism. Carbopol 934P and methocel K4M in the ratio of 1:1 could be used to design
effective and stable buccoadhesive tablets of tebutaline sulphate. 
Pulak  kumar  metia50 et  al.,  (2007) evaluated  novel  mucoadhesive  buccal  tablet  of
oxytocin were prepared as cores in adhesive cups with mucilage (DPM) isolated from edible
Dispyros  peregrine  fruit.  Core  tablets  were  formulated  with  oxytocin  using  permeation
enhancers, sodium taurocholate and sodium thioglycollate. invitro permeation studies of NMBTs
were conducted in franz diffusion cell containing 50 ml phosphate buffer, pH 6.6, at 37±0.20C
through bovine buccal mucosa.
M.V. Ramana51et al  (2007) designed and evaluated mucoadhesive buccal drug delivery
systems containing metoprolol  tartrate.  The mucoadhesive polymers  used in this formulation
were  Carbopol  934,  hydroxylpropylmethylcellulose,  hydroxyethylcellulose  and  sodium
carboxymethylcellulose.  The  formulations  were  characterized  for  physiochemical  parameters,
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invitro  release  studies  and  in-vivo  placebo  studies.The  best  mucoadhesive  performance  and
invitro drug release profile were exhibited by the tablets containing hydroxyethylcelluslose and
Carbopol 934 in ratio 1:2. This product was more comfortable to the user due to absence of
erosion, faster  hydration rate  and less viscosity of  surrounding environment.  In-vivo  placebo
studies did not show any side effect.
Vishnu  M.  Patel52et  al.,  (2007) developed  and  characterized,  chitosan-containing
mucoadhesive buccal patches of propranolol hydrochloride, using the solvent casting method and
chitosan as a bioadhesive polymer and different ratios of chitosan to PVP K-30 were used. The
patches  were  evaluated  for  their  physical  characteristics  like  mass  variation,  drug  content
uniformity, folding endurance,exvivo mucoadhesion strength,exvivo mucoadhesion time, surface
pH,  invitro  drug  release,  and  invitro  buccal  permeation  study.  Patches  exhibited  controlled
release  for  a  period  of  7h.  Incorporation  of  PVP K-30 generally  enhanced  the  release  rate.
Swelling index  was  proportional  to  the  concentration  of  PVP K-30.  Optimized  patches  (F4)
showed satisfactory bioadhesive strength of 9.6 ± 2.0g, and  exvivo  mucoadhesion time of 272
minutes. The surface pH of all patches was between 5.7 and 6.3. Good correlation was observed
between the  invitro  drug release and  invitro  drug permeation with a correlation coefficient of
0.9364. 
Libero ltalo Giannola53et al., (2007) studied  the release of naltrexone (NLX) on buccal
mucosa Permeation  inorder to access the aptitude of NLX to penetrate the mucosal barrier using
Franz  type  diffusion  cells  and  compared  with  data  obtained  by  reconstituted  human  oral
epithelium (100µm) thick. Tablets, designed fro Naltrexone hydrochloride (NLX) administration
on buccal mucosa, were developed and prepared by direct compression of drug loaded (56%)
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poly-octylcyanocrylate  (poly-OCA)  matrices.  NLX  is  slowly  discharged  from buccal  tablets
following Higuchian kinetic. 
Bhupinder  singh54et  al.,  (2006) formulated  and  optimized  of  controlled  release
mucoadhesive tablets of atenolol using response surface methodology using carbopol 934P and
sodium CMC as polymers. Carbopol 934P and sodium carboxymethylcellulose were taken as the
independent variables. Both the polymers had significant effect on the bioadhesive strength of
the tablets measured as the force of detachment against porcine gastric mucosa (P<0.001), the
study  helped  in  finding  the  optimum  formulation  with  excellent  bioadhesive  strength  and
controlled release. Compressed matrices exhibited non-Fickian drug release kinetics approaching
zero-order, as the value of release rate exponent (n) varied between 0.6672 and 0.8646, resulting
in regulated and complete release until 24 h. 
R.C.Doijad55et al., (2006) formulated and evaluated  buccoadhesive drug delivery system
of isosorbide dinitrate for improving bioavailability using solvent casting method and different
bioadhesive polymess like carbopol 934P and carbopol using two different plasticizers PEG and
diethyl  phthalate.  Unidirectional  release  was  achieved  by  preparing  composite  films  with
backing membrane. invitro  studies revealed that release rate of isosorbide dinitrate was higher
from carbopol films containing ratio of Eudragit RL 100 and carbopol in proportion of 1:2 and
2:1, respectively by using both plasticizers. Drug diffusion from buccal films showed apparently
zero order kinetics and release mechanism was diffusion controlled after considerable swelling.
Brunella  Cappello56et  al.,  (2006) developed  cyclodextrin-  containing  poly
(ethyleneoxide) tablets for the delivery of poorly soluble drug carvedilol (CAR) using PEO as
bioadhesive  SR  platform  and  HPβCD  as  modulator  of  drug  release.  When  the  drug  was
incorporated as CAR/HPβCD freeze-dried product, all CAR content was released from the tablet
in about 10 h,  displaying a constant  release regimen after  a transient.  The effect  of HPβCD
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incorporation of the release mechanism was rationalized on the basis of the interplay of different
physical phenomena: erosion and swelling of the tablet, drug dissolution, drug counter-diffusion
and complex formation. 
N.Venkatesan57et  al.,(2006)  studied  on  pharmacokinetic  and  pharmacodynamic
following oral  administration of erythropoietin mucoadhesive tablets to beagle dogs using an
absorption enhancer labrasol in rats and dogs. Tablets were prepared using sylysia 550 (Porous
Silica oxide)  holding the absorption enhancer and carbopol 974 P as a muccoadhesive agent
covered with a water insoluble backing layer of cellulose acetate and a pH sensitive covering
layer of Eudragit L/Eudragit S.
Shaila  Lewis58et  al.,(2006)  designed,  evaluated  and  studied pharmacokinetic  study of
mucoadhesive  buccal  tablets  of  nicotine  for  smoking  cessation.  Three  types  of  tablets  were
developed each containing two mucoadhesive components (HPMC K4M and sodium alginate),
(HPMC K4M and Carbopol), (Chitosan and sodium alginate). For each of these types, batches
were  produced  changing  the  quantity  of  polymers  resulting  in  nine  different  formulations.
Pharmacokinetics  studies  were  conducted  in  smokers.  A  peak  plasma  concentration  of
16.78±2.27  ng  was  obtained  in  2  h.  which  suggest  potential  clinical  utility  in  nicotine
replacement therapy.
Kasshapa Goud H.Desai59et al., (2004) prepared and evaluated, a novel buccal adhesive
system,  containing propranolol  hydrochloride  using special  fabricated  punch and partitioning
medium  as  a  phosphate  buffer  solution  pH  6.6  and  L-octanol  and  permeability  coefficient
through porcine buccal mucosa. NBAS was evaluated by weight uniformity, thickness, hardness,
friability, swelling, mucoadhesive strength, invitro drug release, and invivo human acceptability
studies.  Swelling index  was higher  (4.4)  for  formulations  containing hydroxy propyl  methyl
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cellulose (HPMC) K4M alone, and it decreases with its decreasing concentration in the NBAS.
All NBASs showed higher MS with procine buccal mucosa when compared with that of rabbit
buccal  mucosa. The mechanism of pH release was found to be by non-Fickian diffusion and
followed first order kinetics.
Solimon  Mohammadi-Samani60et  al.,(2004) formulated  and  evaluated  prednisolone
buccoadhesive tablets. The effect of mucoadhesive polymers such as HPMC with viscosity grade
60 and 500 mpas, NaCMC and Cp 934 alone or in combination with each other on the release
profile  of  prdnisolone  was  studied  and  mucoadhesion  strength  of  these  buccoadhesive
formulations was evaluated. The release of prednisolone from HPMC with viscosity grade 60
mpas and Cp 934 alone was fast and there mucoadhesion strength was low. On the other hand,
the release rate  of prednisolone from the HPMC viscosity grade 500 mpas and NaCMC and
mucoadhesion strength were moderate and suitable. The result showed that with different blend
of  HPMC viscosity  grade  500  mpas  or  NaCMC and  Cp  934  with  increasing  in  HPMC or
NaCMC / Cp 934 ratio a remarkable decrease in the rate of drug release and appreciable increase
in the mucoadhesion strength was observed. Except from the formulation prepared with HPMC
viscosity grade 60 and 500 mpas other formulation has more fluctuation in release profiles and
their kinetics of release was not fitted to zero order model.
Luana Perioli61et al., (2004) developed mucoadhesive patches for buccal administration
of ibuprofen  using  several film forming and mucoadhesive polymers. The best film containing
PVP as film forming and NaCMC  as mucoadhesive polymer was loaded with ibuprofen and
invitro and  invivo release studies performed.  Statistical  investigations  of  invitro  drug release
showed that the diffusion was main drug release mechanism and Higuchi’s model provided the
best fit.
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Mario  Jug62et  al.,  (2003) studied  on  influence  of  hydroxypropyl-β-Cyclodextrin
complexation on piroxicam release from buccoadhesive tablets solubility studies included the
formation  PX  (Piroxicam)  and  (HPβCD)  (Hydroxypropyl-β-cyclodextrin)  inclusion  complex
with  1:1  stoichiometry  prepared  and  characterized  by  DSC,  FTIR  and  X-RD.  Tablets  were
prepared  by direct  compression of  hydroxpropylmethyl  cellulose (HPMC) and Carbopol  940
(C940), which showed superior bioadhesion properties compared to HPMC. The invitro release
results demonstrated that matrix tablets containing the PX- (HPβCD) solid complex displayed
faster PX release compared to those containing a physical mixture of “free” drug.
Luana  Perioli63et  al.,  (2003)  studied  on  novel  mucoadhesive  buccal  formulation
containing metronidazole for the treatment of periodontal disease. Mucoadhesive tablets were
developed using different  mixtures  of  cellulose derivates  (Hydroxypropyl  cellulose,  Hydroxy
ethyl cellulose, HPMC K4M, HPMC K15M, Sodium carboxymethyl cellulose) and polyacrylic
derivatives  (Carbomer  940,  Carbomer  971  and  polycarbophil).  The  best  mucoadhesive
performance  and  invitro drug  release  profile  were  achieved  using hydroxyethylcellulose  and
carbomer 940 2:2 ratio.
J.Varshosaz64et al., (2002) developed and characterized buccoadhesive nifedipine tablets
by direct compression of CMC with carbomer which showed superior bioadhesion properties
compared to PVP, PVA, HPMC and acacia.  The tablets containing 30 mg of nifedipine and
various amounts of CMC and CP showed a zero-order drug release kinetic. The adhesion force
was significantly affected by the mixing ratio of CP:CMC in the tablets. The weakest and highest
adhesion force was observed at the mixing ratios of 1:0 and 8:2 of CP: CMC, respectively. The
tablets containing 15% CMC and 35% CP adhered for over 8 h to the upper gums of six healthy
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human volunteers. These tablets released about 56% of the loaded drug after 8 h invivo with a
rate of 2.17 h-1 and were perfectly tolerated.
Juan Manuel  Llabot65et  al .,(2002)  formulated  double  layered  mucoadhesive  tablets
containing  nystatin.  Lactose  CD (direct  compression),  carbomer  (CB),  and  hydroxyl  propyl
methyl celluslose (HPMC) were used as excipients. The immediate release layer was made of
lactose  CD  (100  mg)  and  nystatin  (3o  mg).  The  CB:HPMC  9:1  mixture  showed  the  best
mucoadhesion properties and was selected as excipient for the mucoadhesive polymeric layer
(200 mg). The incorporation of nystatin (33.3 mg) in this layer affected the water uptake, which
in turn modified the erosion behavior. Nystatin showed first-order release. The tablet releases
nystatin quickly from lactose layer and then in a sustained way, during approximately 6 h , from
the  polymeric  layer.  The  mixture  CB:  HPMC 9:1  showed  good  mucoadhesion.  A  swelling
diffusion process modulates the release of nystatin from this layer. A non-Fickian (anomalous)
kinetic was observed. 
Chong-Kook Kim66et al.,  (2000)  formulated and evaluated omeprazole buccal adhesive
tablet  composed  of  sodium alginate,  hydroxyl  propyl  methyl  cellulose  (HPMC),  magnesium
oxide and crosscarmellose sodium. Crosscarmellose sodium enhanced the release of omeprazole
from the tablets.  The analysis  of  the release  mechanism showed that  croscarmellose  sodium
changed the release profile of omeprazole from first- to zero-order release kinetics by forming
porous channels in the matrix tablet matrix. However, it decreased the bioadhesive forces and
stability of omeprazole tablets in human saliva. The tablet is composed of omeprazole-sodium
alginate-HPMC-magnesium  oxide-croscarmellose  sodium  (20:24:6:50:10).  The  plasma
concentration of omeprazole in hamsters increased to reach a maximum of 370 ng/ml at 45 min
after buccal administration and remained at the high level of 146-366 ng/ml for 6 h. The buccal
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bioavailability of  omeprazole  in  hamsters  was 13.7 ± 3.2 %.  These results  demonstrate  that
omeprazole buccal adhesive tablets would be useful to deliver omeprazole which degrades very
rapidly  in  acidic  aqueous  medium  and  undergoes  hepatic  first-  pass  metabolism  after  oral
administration.
Yvonne T.F.Tan67et al., (2000) studied  the effect of carbopol and polyvinylpyrrolidone
on the mechanical, rheological, and release properties of bioadhesive polyethylene glycol gels:
examining the properties of PEG gels that contains different ratios of carbopol 934P and PVP
K90 using texture analyzer  (TA-XT2) and rheometer  (Rheomat 115A). In addition, lidocaine
release from gels was evaluated using a release apparatus simulating the buccal condition. The
results indicated that an increase in CP concentration significantly increased gel compressibility,
hardness, and adhesiveness, factors that affect ease of gel removal from container, ease of gel
application onto mucosal membrane, and gel bioadhesion. All PEG gels exhibited pseudoplastic
flow with thixotropy,  indicating a general  loss of consistency with increased shearing stress.
Drug release T50% was affected by the flow rate of the simulated saliva solution. A reduction in
the flow rate caused a slower drug release and hence a higher T50% value. 
Deepak  Tiwari68 et  al.,  (1999) evaluated  polyoxyethylene  homopolymers  for  buccal
bioadhesive drug delivery device formulation using instrona tensile tester with glass plate and
bovine  sublingual  tissue  as  substrate  surfaces.  Several  BBD  device  formulations  containing
polyoxyethylene  polymer  were  prepared  by  direct  compression  and  compression  molding
processes. The bioadhesive strength of polyoxyethylene polymers appeared to be directly related
to  their  molecular  weights.  The  drug  release  and  the  bioadhesive  strength  of  the  similarly
prepared device formulations appeared to be dependent on the drug:polymer ratios. The elasticity
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of  the  BBD  devices  prepared  by  compression  molding  was  improved  by  the  inclusion  of
polyisobuylene polymer in the formulations. 
Rajesh Khanna69et al.,  (1996) prepared and evaluated bioerodible buccal tablets
containing  clotrimazole,  for  local  delivery  of  clotrimazole  to  the  oral  cavity  using  different
bioadhesive polymers along with soluble excipients like mannitol and PEG 6000. The  invitro
adhesion time and release characteristics were found to be a function of the type of polymer and
also the total composition of the tablets. invitro evaluation of placebo tablets in healthy human
volunteers indicated a linear and positive correlation between the  invitro  and  invivo  adhesion
time.
Taina  Sirkia70 et  al.,  (1993) developed  press-coated  prolonged-release  salbutamol
sulphate tablet were prepared using a compression-coating technique. Salbutamol sulphate was
divided between the core and the coat in the ratio 2:1 or 1:2. Different  viscosity grades and
amounts  of  HPMC  were  used  in  the  coat.  When  HPMC  K100  was  used,  the   release  of
salbutamol sulphate from  tablets with 2/3 of the drug in the core increased with time. The
release patterns obtained in the 1/3 of the drug in the core were biphasic. With other HPMC
grades, the release patterns were best described by zero-order kinetics with 2/3 of the drug in the
core and square-root-of-time kinetics with1/3 of the drug core in the core. For all formulations,
an increase in the amount of HPMC decreased drug release.
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3. RESEARCH INVESTIGATION
3.1. AIM OF THE WORK
Over  the  last  two  decades  mucoadhesion  has  become  of  interest  for  its  potential  to
optimize localized drug delivery,  by retaining a dosage form at the site of action (e.g. within
gastrointestinal tract) or systemic delivery, by retaining a formulation in intimate contact with the
absorption site (e.g. the buccal cavity).
The  present  study  indicates  a  good  potential  of  erodible  mucoadhesive  buccal  films
containing Hydrochlorothiazide for systemic delivery with an added advantage of circumventing
the hepatic first pass metabolism and immediate release. Buccal mucosa is rich in blood supply
which acts as a perfect and fast site for absorption of drug. 
Hydrochlorothiazide is a diuretic drug, frequently used for the treatment of hypertension,
congestive heart failure, symptomatic  edema, diabetes insipidus, renal tubular acidosis, and the
prevention of  kidney stones.  Adverse  effects   of  Hydrochlorothiazide are  High  blood sugar,
Hyperlipidemia, Nausea/vomiting, Weight gain, Gout and Pancreatitis.
The  aim  of  the  present  study  was  to  prepare  and  evaluate  buccal  films  containing
Hydrochlorothiazide with the following objectives.
 To reduce the first pass metabolism
 To overcome the bioavailability problem.
 To improve the patient compliance.
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3.2. PLAN OF WORK
The  present  work  was  carried  out  to  prepare  and  evaluate  buccal  films  of
hydrochlorothiazide, as follows.
 Preparation of buccal films using various combination of different polymers.
 Evaluation of buccal film for the following physical and microbiological parameters.
 Percent moisture absorption
 Percent moisture loss.
 Thickness
 Uniformity of drug content.
 Microbial count.
 Invitro evaluation of buccal film.
 Exvivo evaluation of buccal film in Goat buccal membrane.
 Stability studies 
 Drug release kinetic studies.
  Invivo evaluation of buccal film in rabbits.
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3.3. SUITABILITY OF HYDROCHLOROTHIAZIDE FOR BUCCAL DELIVERY 
SYSTEM
As it is mentioned in the introduction part, the choice of drug should be given careful
consideration.  Suitability  of  hydrochlorothiazide  for  various  important  criteria  should  be
considered as buccal delivery.
Criteria 1:  DRUGS WITH MOLECULUR WEIGHT
Molecular weight of Hydrochlorothiazide is 297.74.
Criteria 2:  DRUG WITH LOW MELTING POINT
Melting point of Hydrochlorothiazide is 273 to 275
Criteria 3: DRUG ABSORTION AND FATE
14C  –  Hydrochlorothiazide  was  administered  orally  (n=4)  and  Iv  (n=2)  to  healthy
subjects. The gastrointestinal absorption ranged between 60% and 80% most of it took place in
the duodenum and the upper  jejunum. The plasma levels  of  HCT detuned according to  2  –
compartment  model,the   half  lives  of  the  alpha  and  beta  phases  being  1.73  and  13.1  h
respectively.Hydrochlorothiazide  accumulated  in  the  blood  cells  and  the  ratio  between  the
radioactivity  in  cells  and  that  in  plasma  averaged  3.5,the  fate  of  a  single  daze  of  14C  –
hydrochlorothiazide, in 2 hypertensive patient treated within the drug chonically was similar to
that  in  the  healthy  subjects.  A  third  person  who  had  slightly  elevated  serum,
creatinine,eliminated.  Hydrochlorothiazide  more  slowly  than  the  others.  Like  the  healthy
subjects, patient eliminated hydrochlorothiazide to greater than 95% in unchanged form.
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4. MATHODOLOGY
4.1. MATERIALS  USED
Table No: 1
S.NO MATERIALS SUPPLIER
1 Hydrochlorothiazide
Hyrodiuril, par pharmaceutical
company,chennai
2 Hydroxy Ethyl cellulose Microlabs,Hosur
3 Carbopol Microlabs,Hosur
4 Hydroxy propyl methyl cellulose Microlabs,Hosur
5 Polyvinyl alcohol
Bombay Lubricants Oil
Company, Mumbai
6 Choloroform. S.D. Fine Chemicals, Boisar
7 Potassium di hydrogen phosphate
Meryer Chemical Technology
Co.,Ltd., Shanghai.
8 Sodium hydroxide
Indenta Chemical Pvt.Ltd.
Mumbai India
9 Methanol S.D. Fine Chemicals, Boisar
10 Acetone S.D. Fine Chemicals, Boisar
11 Glycerol S.D. Fine Chemicals, Boisar
12 Dimethyl sulfoxide Gaylord Chemical Home,USA.
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4.2. INSTRUMENTS USED
Table No:2
S.NO EQUIPMENTS SUPPLIER
1 Vortex  mixture(G560) Remi motors Ltd, Mumbai
2 Centrifuge(KW60) Sharplex Filter Pvt.Ltd., Mumbai
3 Dessicator(A950) Edutek Instrumentation, Ambala.
4 Petridishes Sunshine Instruments, Coimbatore
5 Mini operation table(340294) Medi World,Chennai
6 Magnetic Stirrer(IKA) Remi motors Ltd, Mumbai
7 Double beam UV spectro 
photometer(UVD2950)
Perkin Elmer,Germay.
8 Electronic balance(C151) Swastik ,New Delhi
9 pH-meter(215) Elico Pvt Ltd,Chennai
10 Incubator(030712) M.C.DALAL&CO, Mumbai
11 Freeze Drier(75035) Allied,Mumbai.
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DRUG PROFILE71
HYDROCHLOROTHIAZIDE:
Molecular weight = 297.74
Category :  Inhibitors of Na+, Cl-  (Diuretic , congestive heart failure)
Description : White crystalline powder.
Molecular formula :  C7H8  Cl N3   O4  S2
Solubility :
 Soluble in NaOH , Butyl amine, Dimethyl formamide, Acetone.
 Very slightly soluble in water
 Sparingly soluble in methanol
 Sparingly in soluble in ether CHCL3,mineral acids.
Standards : 
Hydrochlorothiazide  is  2H  –  1,2,4,benzothiazine-  7-sulfonamide  6cholro,3,4dihydro
1,1dioxide.  It  contains  not  less  than 98% and not  more than 102% of  C7H8   Cl N3    O4   S2
calculated with reference to the dried substance.
Storage :
Preserve in well closed container.
4.3. POLYMER PROFILE
4.3.1. HYDROXY PROPYL METHYL CELLULOSE72
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   Molecular weight : 10,000-1,50,000
STRUCTURE:
SOLUBILITY
Soluble in cold water,  certain  grades  of HPMC are  soluble in aqueous
acetone  solution, mixture of dichloro methane and propen-2-ol and other organic solvents.
FUNCTIONAL CATEGORY
Films  former , binder (2-5%), Thickening agent (0.45-1%).
STABILITY AND STORAGE CONDITION
Very stable in dry condition solution staple in pH 3.0 to pH11.0 .
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4.3.2. HYDROXY ETHYL CELLULOSE73
Chemical name : Cellulose , 2 –Hydroxy ethyl ether.
FUNCTIONAL CATEGORY
Coating agent, suspending agent, tablet binder , thickening agent, viscosity increasing 
agent.
DESCRIPTION
Hydroxy ethyl cellulose occurs as a Light tan (or) cream to white coloured , odourless  
and tasteless, hygroscopic powder .
MELTING POINT
Soften at 135oC-1400C  decompose at about 2050C.
MOISTURE CONTENT
Commercially available grades of Hydroxy  ethyl cellulose contains less than 5% w/w of 
water.
SOLUBILITY
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Hydroxy ethyl cellulose is soluble in either hot (or) cold water, forming clear, smooth,
uniform solution practically insoluble in acetone,ethanol, ether, toluene and most other organic
solvents.
APPLICATION IN PHARMACEUTICAL FORMULATIONS
Hydroxy  ethyl  cellulose  is  used  as  a  thickening  agent  in  ophthalmic  and  topical
formulation , although it is also used as a binder and films coating for tablets.
4.3.3. CARBOPOL 934P74
Structural formula:
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Nonproprietary Names BP : Carbomers
PhEur : Carbomera
USPNF : Carbomer
Synonyms Acritamer;  acrylic  acid  polymer;  Carbopol;  carboxy
polymethylene, polyacrylic acid; carboxyvinyl polymer;
Permulen; Ultrez.
Chemical Name Carbomer  [ 9003 – 01 – 4]
Carbomer 910, 934, 934 P, 940, 941, 971 P and 974 P
resins.
Empirical formula Carbomers are synthetic high-molecular weight polymer
of  acryclic  acid  that  are  cross  linked  with  either
allylsucrose  or  allylethers  of  pentaerythitol.  They
contain  between  56%  and  68%  of  carboxylic  acid
(COOH) groups calculated on dry basis.
Molecular Weight 7 X 105  to  4 X 109
Functional Category Bioadhesive,  emulsifying  agent,  release  modifying
agent,  suspending  agent,  tablet  binder,  viscosity  -
increasing agent.
Description Carbomers  are  white-coloured,  mildly  acidic,
hygroscopic powders with slight characteristic odour.
pH 2.7 – 3.5 for a 0.5% w/v aqueous dispersion 2.5 -3.0 for
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a 1% w/v aqueous Dispersion 
Glass transition temperature 100-105ºC
Melting point Decomposition  occurs within 30 min at 2600C
Moisture content 2.0% w/w maximum
Equilibrium moisture content 8 – 10 % w/v  (at 50 RH)
pKa 6.0 ± 0.5
Equivalent weight 76 ± 4
Specific gravity
Density bulk
Density tapped
1.41
1.76 -2.08 g/cm3
1.4 g/cm3
Viscosity 29,400– 39,400   of 0.5% w/v solution.
Stability and storage conditions Carbomers are stable, hygroscopic material that may be
heated at temperatures below 1040C up to 2 h. Without
affecting their thickening efficiency. However, exposure
to excessive temperature can result in discolouration and
reduced stability. 
Carbomer  powder  should  be  stored  in  an  air  tight,
corrosion-resistant  container  in  a  cool  and  dry  place.
The use of glass,  plastic, or resin –lined containers is
recommended.
Incompatibilities Carbomers  are  discoloured  by  resorcinol  and  are
incompatible with phenol, cationic polymer, strong acid
and high levels of electrolytes.
Safety Non - toxic and non –irritant
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Applications In liquid or semi solid pharmaceutical formulations - as
suspending or viscosity- increasing agent, 
In tablets - as binders and as rate controlling excipient
and as bioadhesive material, 
In emulsions - as emulsifying agent.
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5. EXPERIMENTAL INVESTIGATIONS
5.1. STANDARD CURVE FOR HYDROCHLOROTHIAZIDE75
PROCEDURE
Weigh  100  mg  of  hydrochlorothiazide  accurately  and  dissolved  in  little  amount  of
phosphate buffer (pH6.8)76 and the volume is made up with phosphate buffer  to 100ml in a
volumetric flask, from this 2ml was pipette out & transfer in to 100ml volumetric flask, and the
volume is made up with phosphate buffer(pH6.8). From the above1ml was taken and made up
to10ml with  phosphate buffer(pH6.8). The intensity of the resulting solution was measured at
274nm against reagent blank adjusted to zero value. Beer’s law obeyed in this range of 
2-20µg/ml.
TABLE 3:  STANDARD CURVE OF HYDROCHLOROTHIAZIDE
 
FIG 5: STANDARD CURVE OF HYDROCHLOROTHIAZIDE
5.2. FABRICATION OF BUCCAL FILMS
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S.NO
CONCENTRATION
(mcg) ABSORBANCE
1 2 0.11
2 4 0.218
3 6 0.313
4 8 0.406
5 10 0.497
6 12 0.604
7 14 0.716
8 16 0.798
9 18 0.902
10 20 0.984
EXPERIMENTAL INVESTIGATIONS
Films were prepared by the method of casting on glass plate.
FABRICATION OF DRUG RESERVOIR FILMS 
Requited  amount  of  HPMC or  HEC was  dissolved  in  water,  the  previously   mixed
HPMC solution, to this  Glycerin 30% was included and poured over the glass substrate to get
dry film.
FABRICATION OF DRUG RESERVOIR FILM WITH CARBOPOL:
Required amount of  carbopol  was dissolved in water,The previously    mixed carbopol
solution was added to the drug ,to this glycerin 10% was included and poured over the glass
substrate to get a dry film.
COMPOSITION OF HYDROCHLOROTHIAZIDE BUCCAL FILMS
Table: 4
Composition B1 B2 B3 B4 B5 B6 B7 B8 B9
HPMC 3% 4% 5% 4% 4% 4% 4% 4% 4%
HEC - - - 2% 3% 4% 3% 3% 3%
CARBOPOL - - - - - - 1% 2% 3%
GLYCERINE 30% 30% 30% 30% 30% 30% 30% 30% 30%
Each film contain 25mg in drug
Concentration of plasticizer- 30%
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5.3. EVALUATION OF PHYSICAL AND MICROBIOLOGICAL 
CHARATERSICS OF BUCCAL FLIMS 
5.3.1. PERCENT MOISTURE ABSORPTION
The percent moisture absorption test was carried out to check the physical stability of the
buccal films at high humid condition. In the present study the moisture absorption capacity of the
films were determined as follows.
The 1.00cm diameter  films were cut  out  and weighed accurately then the films were
placed in desiccators containing saturated solution of aluminium choloride, keeping the humidity
inside the desiccators 79.5%, after thee days, the films were removed, weighed and percentage
moisture absorption was calculated. Average percentage moisture absorption of the films was
found.
Percent moisture absorption = ×100
5.3.2. PERCENTAGE MOISTURE LOSS
This  test  was   carried  to  check  the  integrity  of  films  at  dry  condition.  The  1.00cm
diameter films was cut out and weighed accurately and kept in a dessicator containing fused
anhydrous  calcium  choloride.  After  72  h  the  films  were  removed  and  weighed.  Average
percentage moisture loss of thee films were found out.
P.M.L=  × 100
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5.3.3. SWELLING INDEX
The films are taken from each batch and it  placed in pH6.8 phosphate buffer and the
weight is measured every three minutes, untill the weight becomes constant.
5.3.4. WATER VAPOUR TRANSMISSION RATE
For  water  vapour  transmission  rate,  glass  vials  of  equal  diameter  were  used  as
transmission cells. These transmission cells were washed thoroughly and dried in oven. About 1
gm of anhydrous calcium chloride was taken in the cells and the polymer films  was fixed over
the brim with the help of the solvent. Cells were accurately weighed, kept in a closed desiccators
containing saturated solution of potassium to maintain a humidity of chloride 84%RH. The cells
were  taken  and  weighed  after  6,12,24,36,48,72h  of  storage.  The  amount  of  water  vapour
transmission was found using the formula. 
Water vapour transmission = 
Water  vapour  transmission  rate  is  usually  expressed  as  the  number  of  grams  of  moisture
gms/h/sq.cm. from the data obtained water vapour transmission was calculated.
5.3.5. THICKNESS
Thickness of the films were measured at six different points using a screw
guage and average thickness of thee films were found out.
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5.3.6. WEIGHT OF BUCCAL FILMS
Each films was weighed individually and average weight of the films were
found out.
5.3.7. FOLDING ENDURANCE 
It was determined  repeatedly by folding a small strip of films at the same place till it
broke. The number of times, the films could be folded at the same place without breaking is the
value folding endurance.
5.3.8. DRUG CONTENT
A film size of 1cm diameter was cut and dissolved in phosphate buffer(pH6.8).  After
adding suitable reagent  and dilution,  optical  density was found out at  274nm. Average  drug
content of thee buccal films were determined.
5.3.9.MEASUREMNT OF BIOADHESIVE STRENGTH OF MUCOADHESIVE DRUG
RESERVOIR FILMS
Mucoadhesive  strength  of  tablet  was  measured  with  porcine  buccal  mucosa  using  a
modified  2-arm  balance.  The  design  of  apparatus  used  while  measuring  the  mucoadhesive
strength is shown in FIG.6.  Porcine buccal mucosa was obtained from a local slaughter house
and stored in phosphate buffer pH 6.8 upon collection. The experiments were performed within 3
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h of procurement of the mucosa. The porcine buccal mucosa was fixed to the stainless steel piece
with cynoacrylate adhesive and then placed in a beaker. Phosphate buffer pH 6.8 was added into
the beaker up to the upper surface of the buccal mucosa to maintain buccal mucosal viability
during the experiments. The film was attached to the upper clamp of the apparatus and then the
beaker was raised slowly until contact between porcine buccal mucosa and film was established.
A preload of 50 g was placed on the clamp for 5 minutes (preload time) to establish adhesion
bonding between tablet and porcine buccal  mucosa.  The preload and preload time were kept
constant for all the formulation. After completion of the preload time, preload was removed from
the clamp and water was then added in the beaker from the burette at a constant rate of 100 drops
per minute. The addition of water was stopped when film was detached from porcine buccal
mucosa.  The  weight  of  water  required  to  detach  film  from  buccal  mucosa  was  noted  as
mucoadhesive Strength, and these experiments were repeated with fresh mucosa in an identical
manner.
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        FIG 6: Illustration of modified apparatus for invitro mucoadhesive strength.
5.3.10. MICROBIAL COUNT
The film strip of different formulation were cut into small circular strips at 1.0 cm in
diameter and aseptically transferred on to a nutrient agar in pertridishes and was moistened by
the addition of 1ml of sterile distilled water. Control plates were also maintained where only 1
ml of sterile distilled water was added. The plates were examined for microbial growth after 24 h
of incubation.
5.4. INVITRO DRUG RELEASE STUDIES OF HYDROCHLOROTHIAZIDE BUCCAL 
FILMS
Commercial semi permeable membrane was employed in this study. The membrane used
was transparent and regenerated cellulose type which was permeable to low molecular weight
substances.
A film  size of 1 cm diameter was cut and placed on the semi permeable membrane. The
semi permeable membrane was tied to one end of an open end cylinder,  which act  as donor
compartment. The entire surface of the membrane was in contact  with receptor compartment
containing 100 ml of phosphate buffer (pH = 6.8). The content of the compartment was agitated
by a magnetic stirrer.
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Sample  of  1  ml  were  withdrawn  from  receptor  compartment  and  replaced  by  equal
volumes of fresh media. The withdrawn samples were analysed using UV spectro photometer at
274 nm using reagent blank.  
5.5. INVIVO DRUG RELEASE STUDIES77
METHODS 
 A healthy rabbit weighing 2.5 to 3kg was taken which was already checked for absence
of any diseases. The fore limbs and hind limbs were tied into the iron of the mini operation table;
so that rabbit was in dorsal position. The prepared film having the size of 1cm containing 20 mg
of hydrochlorothiazide was placed in buccal memberane with the help of clip. Dextrose solution
was transfused continuously thoughout the period of study. Periodically 1ml blood samples were
taken using a syringe which already contained 1ml of 3.8% sodium citrate solution to prevent
blood clotting.  These blood samples  were subjected for  centrifuging  at  2,200 rpm for  about
20minutes.  1ml  of  supernatent  liquid  was  taken  from this  and  after  suitable  dilution  these
samples were analyzed at 274nm using spectrophotometer.
5.6. STABILITY STUDIES78
            The optimized formulation was subjected to accelerated stability storage conditions for 3
months  stored  at  40C,  Room temperature  and  400C/75% RH in  Stability  Chamber.  At  the
interval of one month intervals buccal films were withdrawn and evaluated for various physical
parameters, and invitro drug release.
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6. RESULTS AND DISCUSSION
In the present study the buccal drug delivery system of Hydrochlorothiazide were prepared
by  using  different   hydrophilic  polymer   such  as  HPMC,  HEC,  Carbopol  K-30  by  solvent
evaporation technique.
6.1. PREFORMULATION STUDIES
1) ORGANOLEPTIC EVALUATION OF PURE DRUG 
Hydrochlorothiazide is white or almost white crystalline powder and odorless.
2) BULK CHARACTERIZATION 
2.1. Moisture Content : Moisture content of Hydrochlorothiazide was found to be 0.17%.
2.2. Melting Point :  The melting point of Hydrochlorothiazide determined by open  
  capillary method and was found to be 273-275o C
2.3. Solubility :  Hydrochlorothiazide  soluble in ethanol, poorly soluble in water.
6.2. DRUG-EXCIPIENTS COMPATIBILITY
According to the physical Drug-Excipients compatibility study it was found that the
polymer as well as the excipients selected was compatible with the drug Hydrochlorothiazide.
So the excipients and polymers were selected for formulation.
Table 5:  Drug and Excipients Compatibility.
Sl.
No. Drug :Excipients Ratio
Initial physical
observation
Condition (400C/75%RH)
After 15 days
1 Drug 1:0 White crystalline powder No change
2 Drug:HPMC 1:1 White crystalline powder No change
3 Drug:HEC 1:1 White crystalline powder No change
4 Drug:CARBOPOL 1:1 White crystalline No change
6.3. FT-IR STUDIES:
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The interpretation of FT-IR spectrum of pure drug, polymers and optimized formulation
is shown in table 5
Table 6: Characteristic of IR absorption of HYDROCHLOROTHIAZIDE.
Frequency (cm-1) Groups Assigned
3370-3270 NH or NH2
3030 =CH Aromatic
1600-1550-1520 Hetrocyclic Ring
1600-1450 C=C Aromatic
1370-1335 Asymmetric(SO2)
1180-1160 Symmetric(SO2)
789 (CL2)
Table 7: Characteristics of IR absorption of Formulation batch B8.
Frequency (cm-1) Groups Assigned
1600-1450 C=C Aromatic
1370-1335 Asymmetric(SO2)
1180-1160 Symmetric(SO2)
789 (CL2)
     There is no changes in FTIR peaks indicates that no interaction between drug and excipients.
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6.4.  EVALUATION OF BUCCAL FILMS:
The prepared formulation were subjected to various physico chemical  evaluation test,
such as percentage moisture absorption ,percentage moisture loss, swelling index and time taken
for  maximum  swelling,  water  vapour  transmission  rate,  folding  endurance,  drug  content
uniformity,  thickness  and  bioadhesive  strength.  The  films  were  also  subjected  to   invitro
dissolution studies.
The  physico  chemical  evaluation  of  the  formulation  batch  B8  have  shown  different
physical characteristics of  the formulation changed according to the nature and composition of
polymer.
Dept. Of Pharmaceutics,K.M.College of pharmacy,madurai.         69
RESULTS AND DISCUSSION
Physical characteristics:
The Physical characteristics of the buccal films are given in Table:8
Thickness : The thicknesses of the tablets were found to be 0.426-0.785 mm. 
Drug Content : Drug content in the buccal films were within the limits.
Surface pH : As an acidic  or  alkaline  surface  pH may cause  irritation  to  the
buccal mucosa, the buccal films are formulated to have surface pH as close to neutral as possible
within salivary pH. The surface pH of all the formulations was close to neutral pH and hence,
these formulations may not cause any irritation in the buccal cavity.
The formulation batch B8 (HPMC,HEC,CARBOPOL), have shown highest % moisture
absorption due to high hydrophilicity of the hydrophilic polymer.
The formulation B1 to B3 Shows less percentage moisture absorption , which may be due
to the HPMC polymer.
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Table 8: PHYSICO CHEMICAL EVALUATION OF BUCCAL FILMS OF HYDROCHLOROTHIAZIDE
BATCH
CODE
P.M.A
(±SD)
(%)
P.M.L
(±SD)
(%)
SWELING
INDEX
(±SD)
(%)
WATER
VAPOUR
TRANSMISSION
RATE
(±SD)
(mg/cm2/h)
THICKNESS
(±SD)
(mm)
FOLDING
ENDURANCE
(±SD)
DRUG
CONTENT
(±SD)
(mg)
B1 10.87
±0.031
15.12±
0.53
112.61±
0.57
0.887×
10-3±0.006 0.426±0.001 64±1.12 25.53±0.2
B2 25.04±0.35
21.03±
0.54
127.79±
0.028
1.475×10-
3±0.002 0.572±0.006 61±1.12 24.78±0.2
B3 18.32
±0.33
23.42±
1.25
135.85±
0.43
1.916×
10-3±0.001 0.706±0.006 58.126± 25.04±0.5
B4 11.34±0.05
11.41±
0.24
139.41±
0.38
1.527×
10-3±0.007 0.703±0.007 71±1.56 24.85±0.7
B5 13.79±0.14
12.27±
0.16
153.24±
0.66
1.67×
10-3±0.003 0.572±0.005 64±1.45
24.94±0.8
89
B6 24.26±0.19
22.37±
0.34
148.81±
1.2
1.061×
10-3±0.002 0.675±0.003 60±1.49
24.72±0.0
01
B7 20.03±0.19
16.17±
0.28
152.01±
1.36
2.412×
10-3±0.004 0.785±0.009 82±1.0
24.65±0.0
2
B8 16.79±0.14
13.27±
0.17
156.24±
0.66
2.061×
10-3±0.004 0.671±0.008 67±1.11
25.03±0.0
09
B9 19.69±0.41
25.12±
1.21
140.62±
1.23
2.031×
10-3±0.017 0.719±0.006 58±1.19 25.12±0.3
*PMA  =Percent Moisture Absorption          *PML = Percentage Moisture Loss
6.5.  INVITRO MUCOADHESIVE STRENGTH MEASUREMENT:
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           The results of invitro mucoadhesive strength measurement of Hydrochlorothiazide  buccal
films  are given in table 9 and figure 10
Table 9: Mucoadhesive strength of different formulation batches.
Formulation
Batches
Mucoadhesive
strength
B1 21.15
B2 26.7
B3 24.32
B4 25.1
B5 30.15
B6 28.4
B7 25.2
B8 33.45
B9 28.42
                                                                                    
The  mucoadhesive  strength  of  the  formulations  was  found  to  be  a  function  of  the
concentration of the polymer.
Among the formulations, batch B8  exhibited maximum mucoadhesive strength followed
by those containing HPMC & HEC  and which had higher mucoadhesive strength than HPMC. 
 The order of mucoadhesive strength was,
B8 < B5 < B9 < B6 < B2 < B7 < B4 < B3 < B1
                       Wetting, interpenetration, and mechanical interlocking between mucous and
polymer are the successive stages of mucoadhesion. The strength of mucoadhesion is affected by
various factors such as molecular weight of polymers, contact time with mucous, swelling rate of
the  polymer,  and  the  biological  membrane  used  in  the  study.  This  higher  mucoadhesion  of
carbopol 934P may be due to the ionization of carbopol 934P at salivary pH which leads to
improved attachment of the device to mucosal surface. The superior quality of Carbopol 934P as
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bioadhesive polymer as compared to HPMC K4M and K15M has also been revealed in other
studies.
FIG7: Photograph of modified apparatus for invitro mucoadhesive strength.
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FIG8: Mucoadhesive strength of different formulation batches.
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MICROBIAL COUNT
 
FIG9: Nutrient Agar Medium (control) 
FIG10:T est
The
nutrient agar
in  petri plates
were
examined for
microbial
growth after
24 h of incubation there was no changes observed .
6.6: INVITRO DRUG RELEASE STUDY:
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           As the salivary pH is in the range of 5.8-7.4 and in many studies of buccal drug delivery systems,
pH 6.8 phosphate buffer has been used as drug release medium, so the same has been selected for the
present study.  invitro  release profiles of  hydrochlorothiazide was done formulation from B1 –B9
mucoadhesive table are presented. 
Table 10:      INVITRO DRUG RELEASE DATA FOR B1(3%HPMC)
TIME % DRUG RELEASE CUMULATIVE % DRUGRELEASE
10 20 20
20 38.3 38.5
30 46.4 46.78
40 53.6 54.17
50 65.6 66.14
60 70.4 71.61
Figure 11: INVITRO DRUG RELEASE DATA FOR B1
(3%HPMC)
Table 12: INVITRO DRUG RELEASE DATA FOR B2 (4%HPMC)
TIME %DRUG RELEASE CUMULATIVE % DRUGRELEASE
10 23.2 23.2
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20 35.2 35.43
30 47.2 47.55
40 62.4 62.87
50 71.2 71.83
60 84 84.72
FIG 13: INVITRO DRUG RELEASE DATA FOR B2 (4%HPMC)
Table 13:INVITRO DRUG RELEASE DATA FOR B3
(5%HPMC: 2%HEC)
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TIME %DRUG RELEASE CUMULATIVE% DRUGRELEASE
10 11.2 11.2
20 30.4 30.51
30 42.4 42.70
40 57.6 58.13
50 69.6 70.13
60 74.4 75.10
70 81.6 82.35
FIG 13:INVITRO DRUG RELEASE DATA FOR B3
(5%HPMC: 2%HEC)
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Table 14:   INVITRO DRUG RELEASE DATA FOR B4
(4%HPMC:2% HEC)
 TIME %DRUG RELEASE CUMULATIVE% DRUGRELEASE
10 27.2 27.2
20 39.2 39.29
30 54.4 54.79
40 63.2 63.75
50 71.2 71.84
60 80 80.72
70 89.6 90.41
80 89.6 90.50
FIG 14: INVITRO DRUG RELEASE DATA FOR B4
(4%HPMC:2% HEC)
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Table 15: INVITRO DRUG RELEASE DATA FOR B5
(4%HPMC:3% HEC)
TIME %DRUG RELEASE CUMULATIVE% DRUGRELEASE
10 21.6 21.6
20 37.60 37.82
30 48 48.38
40 63.2 63.68
50 68 68.68
60 74.4 75.08
70 81.6 82.35
80 90.4 91.92
90 92 92.91
FIG 15: INVITRO DRUG RELEASE DATA FOR B5
(4%HPMC:3% HEC)
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Table 16:  INVITRO DRUG RELEASE DATA FOR B6
(4%HPMC:4% HEC)
TIME %DRUG RELEASE CUMULATIVE% DRUGRELEASE
10 21.6 21.6
20 34.4 34.62
30 45.6 45.95
40 49.6 50.06
50 56 56.50
60 61.6 62.10
70 69.6 63.12
80 77.6 78.13
90 84 85.78
FIG 16:INVITRO DRUG RELEASE DATA FOR B6
(4%HPMC:4% HEC)
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Table 17: INVITRO DRUG RELEASE DATA FOR B7
(4%HPMC: 3%HEC:1% CARBOPOL)
TIME %DRUG RELEASE CUMULATIVE% DRUGRELEASE
10 20 20
20 36 36.20
30 41.6 41.96
40 49.6 50.02
50 54 54.50
60 60 60.54
70 63.2 63.80
80 69 69.64
90 72 72.70
100 78.4 79.13
110 81.6 82.39
120 85.6 86.22
FIG 17:INVITRO DRUG RELEASE DATA FOR B7
(4%HPMC:3% HEC: 1%CARBOPOL)
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Table 18: INVITRO DRUG RELEASE DATA FOR B8
(4%HPMC:3% HEC: 2%CARBOPOL)
TIME %DRUG RELEASE CUMULATIVE% DRUGRELEASE
10 23.2 23.2
20 32 32.23
30 39.2 39.52
40 48 48.79
50 53.6 54.08
60 60 60.54
70 64 64.60
80 69.6 70.25
90 73.6 74.30
100 86.4 87.14
110 92 92.87
120 98.4 99.27
FIG 18:INVITRO DRUG RELEASE DATA FOR B8
(4%HPMC:3% HEC:2% CARBOPOL)
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Table 19: INVITRO DRUG RELEASE DATA FOR B9
(4%HPMC:3% HEC:3% CARBOPOL: GLYCERIN)
TIME %DRUG RELEASE CUMULATIVE%PERCENTAGEDRUG RELEASE
10 16 16
20 23.2 23.36
30 29.6 29.83
40 35.2 35.50
50 38.4 38.75
60 46.4 46.79
70 52 52.47
80 57.6 58.12
90 63.2 63.78
100 67.2 67.84
110 71.2 72.04
120 74.4 75.16
FIG 20:INVITRO DRUG RELEASE DATA FOR B9
(4%HPMC:3% HEC:3%  CARBOPOL)
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INVITRO DRUG RELEASE STUDIES:
                        The invitro release profiles of  hydrochlorothiazide from formulation batch B1-B9
buccal films.
             The release was found to depend on the proportion of Carbopol 934P, HPMC and HEC.
The formulations containing(B8) carbopol exhibited higher cumulative amount of drug release.
This may be due to the ionization of Carbopol 934P at pH environment of dissolution medium.
Ionization of Carbopol leads to the development of negative charges along the backbone of the
polymer. Repulsion of like charges uncoils the polymer into an elongated structure, leading to
slightly higher uptake of water. This water uptake leads to considerable swelling of polymer. The
continued swelling causes the drug to diffuse from formulations at faster rate.
In Formulation B1,B2,B3  (HPMC) the  in vitro  drug release were 71.61% at 1 h, 84%
after  1  h  and  82.35% after  1  h10 min  respectively  .The  formulation  B2  has  higher  release
compared to B1 &B3. So the HPMC 4% is optimum to make the formulation with HEC 2 to 4%.
 In formulation B4,B5,B6 the invitro drug release were 90.54% after 1h20min , 92.91%%
at 1h 30min  and 85.78%  after 1h30min  respectively. The hydrophilic polymer is not efficient,
hence the formulation B7 to B9 was formulated with carbopol 1 to 3 %. The  invitro drug
release was 86.22% after 2 h, 99.27% after 2 h ,74.16% after 2 h respectively. 
 In  B8  formulation  invitro  dissolution  study  of  drug  along  with  polymer
(HPMC,HEC,Carbopol) show higher rate of % release of drug . Further increase in concentration
of polymer in B9 formulation the drug release was decreased, From the above report formulation
batch B8 was optimized,and further studies was carried out.
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6.7. KINETICS OF DRUG RELEASE
FIG 21: ZERO ORDER PLOT  FOR BATCH B8
(4%HPMC:3% HEC: 2%CARBOPOL)
FIG 22:FIRST ORDER PLOT  –BATCH B8
4%HPMC:3% HEC: 2%CARBOPOL)
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FIG 23:HIGUCHIS PLOT –BATCH B8
(4%HPMC:3% HEC: 2%CARBOPOL)
FIG 24:PEPPAS PLOT –BATCH B8
(4%HPMC: 3%HEC:2% CARBOPOL)
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The fitting of the release data in first-order,  Korsmeyer Peppas and Higuchi’s model are 
shown in  FIG 21-24.
        The release rate was found to follow first-order release shown by the best fitting
straight line. This behavior has been confirmed by the linear plots obtained with Korsemeyer
Peppas  treatment  of  the data.  Further  the  noncompliance  of  the  data  with  Fickian  diffusion
though matrix is indicated by non linear Higuchi plots.
  6.8. EXVIVO DIFFUSION STUDIES 
An  exvivo diffusion  study  of  hydrochlorothiazide  was  carried  out.  Fresh  goat  cheek
pouch membrane was tied to one end of an open cylinder, which acts as a donor compartment .
The film should be placed in such a way that it should be stuck on the mucous membrane. The
receptor  compartment  was  filled  with  isotonic  phosphate  buffer  pH 6.8.  The  assembly  was
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maintained at 370C and stirred magnetically. Samples were withdrawn at 10 min intervals for 2 h
and analysed using UV- Spectrophotometer at 274nm. 
Table 19: EXVIVO DIFFUSION STUDIES FOR B8
(4%HPMC:3% HEC: 2%CARBOPOL)
Time in minutes Drug release in   Mg
Cumulative % drug 
release
10 2.44 12.4
20 3.66 18.6
30 4.42 22.4
40 6.26 31.8
50 8.40 42.6
60 9.81 49.8
70 10.64 54
80 12.45 63.2
90 13.91 70.6
100 15.05 76.4
110 16.07 81.6
120 16.78 85.2
EXVIVO DIFFUSION STUDIES FOR B8
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FIG 25: (4%HPMC: 3%HEC: 2%CARBOPOL)
   Table: 20
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Time In 
Minutes
Cumulative % drug release
Invitro drug release
studies
Exvivo drug release
studies
Invivo drug release
studies
10 23.2 12.4 4.4
20 32.23 18.6 8.08
30 39.52 22.4 17.44
40 48.79 31.8 26.26
50 54.08 42.6 33.32
60 60.54 49.8 44.47
70 64.60 54 57.65
80 70.25 63.2 66.45
90 74.30 70.6 77.79
100 87.14 76.4 84.46
110 92.87 81.6 89.41
120 99.27 85.2 96.22
RESULTS AND DISCUSSION
Invitro permeation study. 
                     Porcine membrane is identical to human buccal mucosa, so porcine membrane was
used for invitro permeation studies. Very strong bioadhesion could damage the epithelial lining
of the buccal mucosa.
IN VIVO DRUG RELEASE STUDIES 
METHODS 
 A healthy rabbit weighing 2.5 to 3kg was taken which was already checked for absence
of any diseases. The fore limbs and hind limbs were tied into the iron of the mini operation table;
so that rabbit was in dorsal position. The prepared film having the size of 1cm containing 20 mg
of hydrochlorothiazide was placed in buccal membrane with the help of clip. Dextrose solution
was transfused continuously though out the period of study. Periodically 1ml blood samples were
taken using a syringe which already contained 1ml of 3.8% sodium citrate solution to prevent
blood clotting.  These blood samples  were subjected for  centrifuging  at  2,200 rpm for  about
20minites.  1ml  of  supernatant  liquid  was  taken  from  this  and  after  suitable  dilution;  these
samples were analyzed at 274nm using spectrophotometer.
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Table21: INVIVO DRUG RELEASE STUDIES – BATCH 8
(4%HPMC:3% HEC: 2%CARBOPOL)
Time in minutes Amount of drug release Precentage drug release
10 0.4 4.4
20 0.80 8.08
30 1.74 17.44
40 2.62 26.26
50 3.12 33.32
60 4.42 44.47
70 5.7 57.65
80 6.8 66.45
90 7.81 77.79
100 8.23 84.46
110 8.25 89.41
120 9.1 96.22
FIG 27:IN VIVO DRUG RELEASE STUDIES – BATCH 8
(4%HPMC:3% HEC:2% CARBOPOL)
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Table 22: COMPARISON OF INVITRO - EXVIVO DRUG RELEASE STUDIES
Time in minutes In vitro cumulative % drug release Exvivo cumulative % drug
release
10 23.2 12.4
20 32.23 18.6
30 39.52 22.4
40 48.79 31.8
50 54.12 42.6
60 60.52 49.8
70 64.6 54
80 70.25 63.2
90 74.32 70.6
100 87.14 76.4
110 92.72 81.6
120 99.27 85.2
FIG28:IN VIVO– IN VITRO CORRELATION PLOT
 
Dept. Of Pharmaceutics,K.M.College of pharmacy,madurai.         93
RESULTS AND DISCUSSION
Table 23: COMPARISON OF INVITRO – INVIVO DRUG RELEASE STUDIES
Time in Minutes Cumulative % drug release
(INVITRO)
Cumulative % drug release
(INVIVO)
10 23.2 4.4
20 32.23 8.08
30 39.52 17.44
40 48.79 26.26
50 54.08 33.32
60 60.54 44.47
70 64.6 57.65
80 70.25 66.45
90 74.3 77.79
100 87.14 84.46
110 92.87 89.41
120 99.27 96.22
FIG 28:IN VIVO– IN VITRO CORRELATION PLOT
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7.9. STABILITY STUDIES
 PHYSICAL PARAMETERS: 
The  optimized  formulation  batch  B8  did  not  show  any  significant  changes  in  the  physical
parameters and results were within limits. The results were shown in table 24.
Sl.
No Parameters
40C Room Temperature 40
0C/ 75% RH
(Stability chamber)
Initial 7Days
15
Days
30
Days
7
Days
15
Days
30
Days 7 Days
15
Days
30
Days
1 INVITRO %drug release 0 98.7 97 97
98.5 95 92 95 89 85
2 DrugContent (%) 99.1 99.1 98.6 98.8 99.1 98.1 98.1 98.8 98.3 98.1
3 Surface pH 6.8 6.8 6.8 6.8 6.8 6.8 6.7 6.8 6.7 6.7
Table 24
The optimized formulation batch B8 did not show any significant changes in drug
release profile after a period of 3 months. Hence it can be concluded that the optimized batch B8
is stable at an accelerated storage conditions.
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7. CONCLUSION
Efforts should be made to develop standard invitro method to characterize and compare
different material and formulation in terms of their capability to promote drug absorption via the
buccal route.
Buccal  adhesive  systems  offer  innumerable  advantages  in  terms  of  accessibility,
administration and withdrawal,  retentively,  low enzymatic activity,  economy and high patient
compliance.
Adhesions of these drug delivery devices to mucosal  membranes lead to an increased
drug  concentration  gradient  at  the  absorption  site  and  therefore  improve  bioavailability  of
systemically delivered drugs.
The  results  of  the  study  show that  therapeutic  levels  of  Hydrochlorothiazide  can  be
delivered through buccal, formulation batch B8 show good swelling, a convenient residence time
and promising controlled drug release thus seems to be a potential candidate for the development
of buccal film for effective therapeutic use.  Invivo studies need to be designed and executed to
substantiate further invitro - invivo correlation.
The main advantages of the buccal route of administration over the traditional per oral
route are that drug degradation in the stomach, first-pass metabolism is avoided, and therapeutic
drug  levels  of  drug  can  be  achieved  rapidly.  The  future  direction  of  buccal  adhesive  drug
delivery lies in vaccine formulations and delivery of small proteins/ peptides.
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